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Abstract 
In Canada, there is a lack of data regarding broad-spectrum β-lactamase producing E. coli in 
chickens. This thesis aimed to identify and characterize broad-spectrum β-lactamase producing 
E. coli in chickens coming from small and large-scale flocks. 
Chickens coming from small-scale flocks are not included as part of the Canadian national 
antimicrobial resistance surveillance program. We performed our study on this understudied bird 
population to identify broad spectrum β-lactamase producing E. coli. Following PCR and DNA 
sequencing in order to identify resistance genes, isolates were further characterized by PFGE to 
determine their relatedness. A subset of samples was subjected to MLST to determine if human 
resistance pandemic clones (E. coli ST131) were present in this chicken population. CTX-M-1 
and CMY-2 were identified as predominant ESBL and AmpC β-lactamase genes. The population 
was genetically heterogeneous, only 32 out of 226 isolates formed clusters. None of the isolates 
were tested by MLST were ST131. 
We also conducted a comparative study of archived samples from chickens raised in large-scale 
flocks; stored samples were screened for 3rd generation cephalosporin resistance using 
CHROMagar ESBL (selective media). The results of this testing were compared to the findings 
of CIPARS to determine the value of including selective media in resistance surveillance 
programs. Following antimicrobial susceptibility testing by microbroth dilution, isolates resistant 
to 3GC were screened for ESBL and AmpC producing genes using PCR. The majority of the 
isolates were multi-drug resistance. Like chickens from small-scale flocks, CTX-M-1 and CMY-
2 were found to be the predominant broad-spectrum β-lactamases. 
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This is the first systematic documentation of the types of β-lactamases produced by E. coli 
isolated from Canadian chickens. We found chicken from both small and large flocks carried 
broad-spectrum β-lactamase genes conferring resistance to extended-spectrum cephalosporins. 
Further, our findings suggest that resistance is spreading in chickens via mobile genetic elements 
rather than clonal transfer. Because different β-lactamases were identified among poultry isolates 
than are common among human clinical isolates, our findings suggest that E. coli from Canadian 
chicken may pose a lower risk to public health than previously thought. More research is 
required to evaluate the magnitude of the risk of poultry borne drug resistant E. coli to public 
health.  
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1 Introduction and Literature review 
1.1 Antibiotic resistance 
1.1.1 General introduction to the problem of antimicrobial resistance 
The discovery of antibiotics was a revolutionary achievement for both human and 
veterinary medicine. Since the discovery, antimicrobials have cured humans and animals from 
bacterial infections (Byarugaba, 2010). Antimicrobials can be defined as any natural, synthetic or 
semisynthetic origin substance which kill or inhibit the growth of microorganisms (Giguère, 
2013; Guardabassi and Courvalin, 2006; Maartens et al., 2011). In contrast, antibiotic refers to a 
low molecular weight substance produced by microorganisms which act against another 
microorganism at low concentrations (Giguère, 2013; Guardabassi and Courvalin, 2006; 
Maartens et al., 2011). The term antibiotic has been used interchangeably with the term 
antimicrobial in many instances (Giguère, 2013). 
The first antibiotic was penicillin discovered by Alexander Fleming in 1928 and was first 
used therapeutically in the 1940s. However, treatment failures and bacteria resistant to penicillin 
were first noticed immediately after the discovery of penicillin (as reviewed in Aminov, 2010; 
Byarugaba, 2010; Ventola, 2015). Even Alexander Fleming warned that bacteria could become 
resistant to these remarkable drugs in his Nobel Prize speech in 1945 (WHO, 2014). Indeed, each 
new antibacterial drug development has been followed by the detection of resistance to it. 
Antibiotic resistance is defined as the ability of microbes to resist the effects of drugs, as a result 
the drugs become ineffective to neither kill nor inhibit the microbes (CDC, 2015; WHO, 2014). 
Antimicrobial resistance in bacteria results from selection pressures applied by antimicrobial use 
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(McDermott et al., 2002; WHO, 2014). Use of antibiotic can trigger the antimicrobial resistance 
by exerting selection pressure on bacterial strains (McDermott et al., 2002). 
The emergence and rapid spread of antimicrobial resistance is now a global concern 
(Laxminarayan et al., 2013; Ventola, 2015; WHO, 2014). In addition to the prospect of 
untreatable infections, antimicrobial resistance results in higher economic costs due to longer 
hospital stays in infected patients, the requirement for additional diagnostics and more expensive 
drugs. In the United States, the economic burden from excess medical expenditures due to 
antimicrobial resistance is estimated to be approximately $20 billion each year (Marston et al., 
2016). In the United States, more than 2 million infections and approximately 23,000 deaths are 
associated with antimicrobial resistant organisms annually (CDC, 2015), while approximately 
25,000 annual deaths are attributed to resistance in Europe (Marston et al., 2016). 
1.1.2 Mechanism of resistance and mode of transfer 
Antibiotics work on bacterial cells in different ways and understanding of these 
mechanisms along with the chemical nature of antimicrobial agents is important to have a better 
understanding of antimicrobial resistant developments (Figure 1.1). Five different mechanisms 
of action are briefly described below: 
Inhibition of the cell wall synthesis: β-lactam drugs (eg: penicillin, cephalosporin etc.) 
and the glycopeptides (eg: vancomycin) act in this way (Mcdermott et al., 2003; Wright, 2010). 
The β-lactam drugs possess the β-lactam ring which is the functional unit of this group of 
antibiotics. The β-lactam ring binds with bacterial penicillin-binding proteins (PBPs) located in 
bacterial cell membrane thus prevent cross-linking in peptidoglycan synthesis and inhibit the 
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bacterial cell wall synthesis (Džidić et al., 2008; Livermore and Woodford, 2006; Mcdermott et 
al., 2003; Tenover, 2006). 
Inhibition of protein synthesis: In bacteria, ribosomes play role in protein synthesis and 
they are structurally different than eukaryotic ribosomes (Walsh, 2000). Some antibiotics (eg: 
macrolides, aminoglycosides, tetracyclines, chloramphenicol) can interfere with bacterial 
ribosome function by binding with its structural subunits (either 30s or 50s) and thus inhibiting 
protein synthesis. Tetracyclines, aminoglycosides bind to the 30s ribosomal subunit while 
chloramphenicol, macrolides bind to 50s subunit (Džidić et al., 2008; Tenover, 2006). 
Inhibition of nucleic acid synthesis: Quinolones and fluoroquinolones inhibit nucleic 
acid synthesis by binding to DNA gyrase and DNA topoisomerase IV. These enzymes are 
responsible for relaxing and supercoiling the DNA within a cell. Binding with these enzymes can 
interfere with the DNA replication process. Another drug rifampicin binds bacterial DNA-
dependent RNA polymerase and thus inhibits RNA synthesis (Džidić et al., 2008; Tenover, 
2006; Walsh, 2000). 
Inhibition of folate synthesis: Sulfonamides and trimethoprim act by interfering with 
folate synthesis. Sulfonamides inhibit the bacterial folate synthesis by excluding para-
aminobenzoic acid (PABA) incorporation into the folic acid molecule through competing for the 
enzyme dihydropteroate synthetase while trimethoprim directly inhibits the dihydrofolate 
reductase enzyme (Džidić et al., 2008; Mcdermott et al., 2003; Tenover, 2006). Most of the time 
sulfonamides and trimethoprim are used combined for synergism (Smith and Powell, 2000). 
Inhibition of cell membrane function: Polymyxin and daptomycin kill the bacteria in 
this way. This is not a well-defined mechanism; it is hypothesized that polymyxins increase the 
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bacterial permeability resulting in leakage of bacterial content which leads to bacterial cell death. 
Daptomycin binds to the bacterial cell membrane and can kill the bacteria because of potassium 
efflux from the bacterial cell (Džidić et al., 2008; Tenover, 2006). 
Resistance can be either intrinsic or acquired. Intrinsic resistance defines the lack of 
bacterial inherent structural or functional properties which is required for the antimicrobial to act 
(Blair et al., 2015; Guardabassi and Courvalin, 2006; Mcdermott et al., 2003). Intrinsic resistance 
is constitutive to bacterial genera or species without the requirement for the acquisition of novel 
genetic material. An example of intrinsic resistance is the lipopeptide daptomycin which is 
effective against Gram-positive bacteria but is not effective against Gram-negative bacteria due 
to differences in cell membrane structure (Blair et al., 2015). Bacteria can acquire antimicrobial 
resistance either by chromosomal mutation and acquisition of resistance genes by horizontal 
transfer (Blair et al., 2015; Catry et al., 2003; Džidić et al., 2008; Guardabassi and Courvalin, 
2006; Ruppé et al., 2015). Mutation in chromosomal genes can occur in a variety of ways such as 
spontaneous mutation, hypermutator and adaptive mutagenesis (Džidić et al., 2008). Horizontal 
gene transfer is the transfer of genetic material between individual bacteria of same species or 
different species. This mechanism of gene transfer is one of the important means of 
dissemination of antibiotic resistance genes among bacteria. Different transposable genetic 
elements such as plasmids, transposons, gene cassettes play an important role in carrying 
resistance genes and three major mechanisms by which bacteria transfer gene horizontally are 
conjugation, transformation and transduction (Babic et al., 2006; Drawz and Bonomo, 2010; 
Huddleston, 2014; Mcdermott et al., 2003; Wright, 2005). 
Conjugation: During conjugation, two bacterial cells (donor and recipient) come into 
contact with each other and they form a channel via pilus or pore that allows the transfer of 
5 
 
genetic material from donor cell to recipient. Bacterial plasmids mainly transfer via conjugation 
mechanism, however other mobile genetic elements such as transposons can also be transferred 
via conjugation (Huddleston, 2014; Thomas and Nielsen, 2005). 
Transformation: In this process, bacteria acquire the free DNA from environment and 
incorporate them into their own genome. In brief, bacteria take up the free DNA from the 
environment which has been released by another bacterium. This DNA is then incorporated  into 
their genome either by homologous or illegitimate recombination and finally, the newly 
incorporated DNA will be expressed in the recipient cell (Huddleston, 2014). 
Transduction: In this process, antibiotic resistance genes are transferred via 
bacteriophages. During the replication process, bacteriophages accidently acquire host or donor 
genomic DNA. Once, the bacteriophage lyses the host cell they are released into the 
environment. These new phages then infect new bacterial host and transfer their acquired 
genome into the new recipient bacteria (Arber, 2014; Huddleston, 2014). 
Bacterial resistance can be classified into several mechanisms which broadly fall into 
three groups - inactivation of antibiotic, altering or modification of antibiotic target and 
minimizing intracellular concentration of antibiotics (Blair et al., 2015; Dever and Dermody, 
1991; Wright, 2011). 
Inactivation of antibiotic: Antibiotics can be inactivated by bacterial enzymatic 
hydrolysis or modification (Blair et al., 2015; Džidić et al., 2008; Kong et al., 2010). β-
lactamases are enzymes that many Gram-negative bacteria produce which can degrade β-lactam 
drugs. These enzymes hydrolyze the β-lactam ring which is a functional unit of this group of 
antibiotics thus rendering the antibiotics inactive (Blair et al., 2015; Bonnet, 2004; Kong et al., 
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2010; Walsh, 2000; Wright, 2011). Antibiotics can also be inactivated by transferring a chemical 
group to their vulnerable sites by bacterial enzymes which prevents the antibiotics from binding 
to its target protein (Blair et al., 2015; Džidić et al., 2008; Wright, 2011) A number of different 
chemical groups such as adenyl, phosphoryl, or acetyl can be transferred to the antibiotic site by 
antimicrobial resistant enzymes transferase and thus modified the antibiotic (Blair et al., 2015; 
Džidić et al., 2008; Wright, 2011). Aminoglycosides, chloramphenicol, streptogramin, 
macrolides and rifampicin can be inactivated by these group transfer process (Džidić et al., 
2008). 
Altering or modification of antibiotic target: Target site modification can inhibit 
antibiotic function by making them unable to bind properly (Walsh, 2000). Mutational changes 
in bacterial structure can prevent the antibiotic from binding properly while retaining cellular 
functions. β-lactam, aminoglycosides, tetracyclines, fluoroquinolones, macrolides etc. are some 
of the drugs which can be inhibited by target alteration (Blair et al., 2015; Džidić et al., 2008; 
Mcdermott et al., 2003). For example, β-lactam drugs target bacterial peptidoglycan layer, 
however, mutation in bacterial PBPs can result in lower affinity to β-lactam drugs and thus 
confer resistance to them (Džidić et al., 2008). 
Minimizing intracellular concentration of antibiotics: Active efflux pumps and outer 
membrane permeability of bacteria can minimize the antibiotic concentration into the cell and 
thus confer resistance (Džidić et al., 2008; Wright, 2011). Resistance to many antibiotics such as 
tetracyclines, chloramphenicol, macrolides, fluoroquinolones andaminoglycosides occurs in this 
way (Dever and Dermody, 1991; Mcdermott et al., 2003; Wright, 2010). For example, tetA, tetB 
and tetC are the genes which can encode efflux pumps which reduce the concentration of 
tetracycline within bacterial cells conferring resistance. Changes or down-regulation in porin 
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expression can affect the ability of antibiotics to enter the bacterial cell. β-lactams, 
chloramphenicol, and fluoroquinolones are the drugs which use porin channel to enter into the 
Gram-negative bacteria, changes in porin expression can therefore inhibit these antibiotics 
(Džidić et al., 2008).  
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Figure 1.1: Antimicrobial targets and mechanism of antimicrobial resistance. Antimicrobial 
targets are highlighted on the left (grey) and mechanisms of resistance are listed on the right 
(green). Figure adapted from (Wright, 2010). 
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1.1.3 Antimicrobial resistance in Gram-negative bacteria 
Antibiotic resistance is a complex and long standing problem in both Gram-positive and 
Gram-negative bacteria, however, resistance in Gram-negative bacteria is currently the most 
pressing issue (Kuenzli, 2016; Laxminarayan et al., 2013; Paterson, 2006). In Gram-negative 
bacteria, broad-spectrum β-lactamase resistance has increased globally due to indiscriminate 
antimicrobial use in humans and animals. Extended-spectrum β-lactamase (ESBL) producing 
Enterobacteriaceae are a major concern as these enzymes confer resistance to some important 
class of drugs such as penicillin, amoxicillin, 3rd generation cephalosporin (3GC) (Dahms et al., 
2015; Kuenzli, 2016; Overdevest et al., 2011; Rubin and Pitout, 2014). A study found 1.7 times 
higher hospital cost for urinary tract infection caused by ESBL producing E. coli and Klebsiella 
sp comparing with other causal agents (Lee et al., 2006). Besides these, multi-drug resistance 
(MDR) is another threat for Gram-negative bacteria which limits the ability for clinicians to treat 
community onset infections (Vasoo et al., 2015). Besides health care related infections, ESBL 
producing Enterobacteriaceae were identified from community acquired infections (Kuenzli, 
2016). Recently carbapenem-resistant Enterobacteriaceae including those producing New Delhi 
metallo β lactamase (NDM) and Klebsiella pneumoniae carbapenemase (KPC) have emerged 
which confer resistance to these drugs of last resort. Increased patient mortality rates are 
associated with carbapenemase producing Enterobacteriaceae (Vasoo et al., 2015). 
1.1.4 Broad-spectrum β-lactamases 
β-lactam antibiotics are important drugs in treating infections caused by many common 
bacterial pathogens including E. coli. In 2009, total antibiotic sales were 42 billion US dollars 
globally (Hamad, 2010). Antibiotics of β-lactam family contribute 65% to the total antibiotic 
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market worldwide (Thakuria and Lahon, 2013). This class consists of penicillins, cephalosporins, 
carbapenems, cephamycins, and monobactams (Holten and Onusko, 2000). β-lactam antibiotics 
bind with the PBPs of bacterial cell membrane and thus inhibit the cell wall synthesis. β-
lactamases hydrolyse the β-lactam ring, thus inactivate these antibiotics (Džidić et al., 2008; 
Livermore and Woodford, 2006; Mcdermott et al., 2003; Paterson, 2006; Tenover, 2006; Walsh, 
2000; Wright, 2011). Genes encoding β-lactamase enzymes can be found either chromosomally 
or on mobile genetic elements which includes plasmids, gene cassettes, or transposons (Babic et 
al., 2006; Drawz and Bonomo, 2010; Wright, 2005). β-lactamases are a broad group of enzymes 
have been classified using two schemes - (a) Ambler molecular classification and (b) Bush-
Jacoby-Medieros functional classification. In the Ambler classification system, β-lactamases are 
grouped according to protein sequence similarity. There are four classes (A - D) in the Ambler 
scheme where class A, C and D are serine β-lactamases and class B are metallo β-lactamases 
(Ambler et al., 1991; Bush et al., 1995; Paterson and Bonomo, 2005). Conversely, functional 
similarities (substrate and inhibitor profile) of the enzymes are the basis of Bush-Jacoby-
Medieros classification (Bush and Jacoby, 2010). Classification of β-lactamase enzyme is 
summarized in Table 1.1. Extended-spectrum β-lactamases (ESBLs), plasmid-mediated AmpC 
β-lactamases and carbapenemases are the emerging enzymes in Enterobacteriaceae which are 
increasingly problematic (Pitout, 2012a). 
Extended-spectrum β-lactamases (ESBLs): ESBLs are class A enzymes according to 
the Ambler classification. They can degrade broad-spectrum β-lactams which include penicillins, 
cephalosporins, and monobactams but not the cephamycins or carbapenems. These enzymes can 
be inhibited by β-lactamase inhibitors such as clavulanic acid, tazobactam or sulbactam (Chong 
et al., 2011; Paterson and Bonomo, 2005). SHV (except SHV-1), TEM (except TEM- 1, 2 and 
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13) and CTX-Ms are examples of some of the most common ESBLs presently. The parent 
enzymes SHV-1 and TEM-1, 2 and 13 can hydrolyze penicillin and first generation 
cephalosporins and be inhibited by clavulanic acid, but due to their narrow spectrum of activity 
are not considered to be ESBLs. Later, a number mutant of these parent enzymes has been 
discovered which having broad spectrum of activity are considered as SHV and TEM type 
ESBLs (Paterson and Bonomo, 2005; Rubin and Pitout, 2014). As of March 2017, 193 SHV and 
223 TEM variants have been described (http://www.lahey.org). The CTX-M enzymes are a new 
family of ESBLs whose broad spectrum did not arise as a result of mutation from existing 
enzymes like TEM and SHV ESBLs, rather these were acquired by horizontal gene transfer from 
Kluyvera sp (Pitout, 2012a; Rubin and Pitout, 2014). The name CTX-M refers to the preferential 
hydrolytic activity of the enzymes against cefotaxime than ceftazidime, and “M” refers to 
Munchen where these enzymes were first described (Paterson and Bonomo, 2005; Rubin and 
Pitout, 2014). The number of CTX-M variants is increasing and as of March 2017, 172 variants 
of CTX-M were identified worldwide (http://www.lahey.org). The CTX-M enzymes can be 
classified into phylogenetic subgroups CTX-M-1, CTX-M-3, CTX-M-8, CTX-M-9, CTX-M-15 
and CTX-M-25 based on clustering of their amino acid sequences (Bonnet, 2004; Hawkey and 
Jones, 2009). 
Plasmid-mediated AmpC β-lactamases: This group of enzymes is class C based on 
Ambler classification, and group 1 according to the Bush-Jacoby-Medieros system (Jacoby, 
2009). Although AmpC enzymes are structurally very similar to class A β-lactamases, they differ 
in that class C enzymes have more open binding sites for cephalosporins (Jacoby, 2009). These 
enzymes confer resistance to a broad spectrum of antibiotics which includes penicillin, 
cephalosporins, monobactams and cephamycins (Jacoby, 2009). Cloxacillin, oxacillin and 
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azetronam are good inhibitors of AmpC enzymes whereas these enzymes are poorly be inhibited 
by Class A enzymes inhibitors such as clavulanic acid, sulbactam and tazobactam (Jacoby, 
2009). AmpC β-lactamase was first detected enzyme from E. coli which were resistant to 
penicillin while plasmid-mediated AmpC (pAmpC) genes were reported from Enterobacter 
cloacae in 1980s (Philippon et al., 2002). CMY, ACT, FOX, ACT, and DHA types are some of 
the examples of AmpC β-lactamases which derived from chromosomally encoded AmpC 
cephalosporinases of bacteria such as Enterobacter spp., Citrobacter freundii, Morganella 
morganii, Aeromonas spp and Hafnia alvei (Rubin and Pitout, 2014). The Lahey database is a 
curated list of β-lactamase genes, as of March 2017 a total 136 variants of CMY have been 
described (http://www.lahey.org). 
Carbapenemases: Carbapenemases are a group of enzyme which are capable of 
hydrolyzing all classes of β-lactam drugs including carbapenems which are considered to be the 
last resort antimicrobial drugs (Nordmann et al., 2011). Carbapenemases fall into two major 
molecular families; metallo-β-lactamases and serine-β-lactamases (Queenan and Bush, 2007). 
Metallo β-lactamases (MBLs) differ structurally from the other β-lactamases by their 
requirement for at least one zinc atom at the active site which facilitates them to hydrolysis β-
lactam drugs (Queenan and Bush, 2007). MBLs can be inhibited by metal ion chelators, such as 
EDTA and dipicolinic acid (Laraki et al., 1999), but are uninhibited by clavulanic acid, 
tazobactam or sulbactam. MBLs are Ambler class B and functional group 3 (Queenan and Bush, 
2007). Verona integron encoded metallo β-lactamase (VIM), Imipenemase (IMP) and recently, 
New Delhi metallo β-lactamase (NDM) are the most common types of MBLs (Nordmann et al., 
2011). Unlike MBLs, serine β-lactamases contain a serine at their active site. Metal ion chelators 
like EDTA do not inhibit these enzymes (Queenan and Bush, 2007). Serine β-lactamases belong 
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to Ambler class A and D. A variety of enzymes have been described within class A 
carbapenemases, some of them are chromosome-mediated such as SME, NMC-A, IMI-1, while 
some are plasmid mediated such as the KPC, IMI-2, GES (Queenan and Bush, 2007). In fact, 
plasmid-mediated KPC is the most commonly identified class A carbapenemase worldwide 
(Nordmann et al., 2011). Oxacillinases (OXA) with carbapenemase activity categorized as class 
D enzymes, have been extensively reported throughout the world (Nordmann et al., 2011). The 
OXA enzymes are a diverse family of β-lactamases including OXA-48, OXA-181 (Nordmann et 
al., 2011; Queenan and Bush, 2007). 
  
  
Table 1.1: Classification of β-lactamases enzymes (Bush and Jacoby, 2010; Kanj and Kanafani, 2011; Rubin and Pitout, 2014) 
Ambler 
Classification 
Bush-Jacoby-
Medeiros 
Group 
Active site Enzyme Examples 
Spectrum of 
resistance 
Inhibitors 
A 
2be, 2br, 2c, 
2e, 2f 
Serine 
ESBLs 
TEM (except TEM-
1, 2 and 13), SHV 
(except SHV-1), 
CTX-M 
Penicillin, 
cephalosporin,  
Monobactam Clavulanic acid, 
tazobactam, 
sulbactam 
(except 2br) Carbapenemases 
(KPC type) 
KPC 
Penicillin, 
cephalosporin,  
monobactam, 
meropenem 
cephamycin 
B 3a 
Zinc-binding 
thiol group 
Carbapenemases 
(Metallo β-lactamases) 
NDM, VIM, IMP All β-lactams 
EDTA and other 
metal chelators 
C 1 Serine AmpC CMY-2, FOX, ACT,  
Penicillin, 
cephalosporin, 
cephamycin, 
monobactam 
Cloxacillin, 
boronic acid 
D 2df Serine Oxacillinase  OXA-1, OXA-48 
Penicillin, 
carbapenem 
NaCl 
 
 
1
4
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1.1.5 Integrons in Gram-negative Bacteria 
In Gram-negative bacteria, integrons play an important role in horizontal resistance gene 
transfer between bacteria. Integrons are genetic element structured with three distinct 
components: integrase gene (intI), gene cassette receptor site (attI) and a promoter (Pc) which 
can recognize and carry gene cassettes on it (Hall and Collis, 1995). This integrase gene (intI) 
encodes integrase enzyme which facilitates the site specific insertion of gene cassettes on the 
gene cassette receptor site (attI) and once cassettes are inserted at attI, promoter expresses the 
gene cassettes associated gene (Michael et al., 2004). Integrons are not mobile themselves, but 
the gene cassettes within them can be independently mobilized (Fluit and Schmitz, 2004). Gene 
cassettes are small elements which can be incorporated into an integron or exist as a free, circular 
DNA molecules (Bennett, 1999; Hall and Collis, 1995). The gene cassette is a non-replicating 
mobile genetic element lacking its own promoter and is therefore expressed under the influence 
of the promoter within the integron. During the integration process, the attI of integron and attC 
of gene cassette consists of a core sequence where the site-specific recombination takes place. 
Gene cassette expression level varies with distance from the promoter; those near the promoter 
are expressed more strongly than cassettes more distant to the promoter (Bennett, 1999). 
Integrons may carry multiple gene cassettes, up to 8, resulting in multidrug resistance (Rowe-
Magnus and Mazel, 2002). Integrons are categorized into three distinct classes: class 1, class 2 
and class 3. Class 1 integrons are the most frequently identified integrons from various clinical 
isolates (Bennett, 1999; Fluit and Schmitz, 2004). The class 1 integron consists of 5’ and 3’ 
conserved regions (CR) separated by variable region. Gene cassettes are found within the 
variable region (Bennett, 1999). The essential features of class I integron like intI, attI and 
promoter all accommodated in the 5’ CR, while 3’ CR consists of genes sul1, which encodes 
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resistance to sulphonamides, a truncated qacΔE1, that has been shown to increase the minimum 
inhibitory concentration of benzalkonium chloride (Bennett, 1999). A variety of gene cassettes 
are associated with class 1 integrons, however, aadA gene cassette is most common (Fluit and 
Schmitz, 2004). Class 1 integrons containing gene cassettes has been identified to be frequent 
encoder of streptomycin-spectinomycin, trimethoprim and β-lactam resistance (Deng et al., 
2015; Sandvang, 1999). These integrons are commonly located on plasmids which mediate rapid 
transfer to other organisms via conjugation (Fluit and Schmitz, 2004). 
  
1.2 Epidemiology of antimicrobial resistant Escherichia coli in humans and 
animals in Canada 
1.2.1 Broad-spectrum β-lactamases in human isolates 
Drugs within the β-lactam family are the treatment of choice for treating a wide variety of 
community onset bacterial infections caused by Gram-negative bacteria (Shaikh et al., 2015). 
However, the emergence of resistance towards these drugs limits the clinicians ability to use 
existing drugs effectively. Organisms producing “newer β-lactamases” including the ESBLs, 
plasmid-mediated AmpC and carbapenemases are increasingly encountered in community 
settings throughout the world including Canada (Pitout, 2012a). ESBLs are most often associated 
with E. coli, K. pneumoniae and other members of the Enterobacteriaceae family. Following 
SHV and TEM type ESBLs, the CTX-M type enzymes have gained prominence throughout the 
world since 2000’s (Pitout, 2012a). Among the diversity of variants of CTX-M identified from 
clinical isolates, CTX-M-14 and CTX-M-15 are the most prevalent around the world (Pitout, 
2012a). In Canada, CTX-M-15 were identified as most predominant ESBL from hospital patients 
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(Baudry et al., 2008; Peirano et al., 2012). Multi-locus sequencing typing has identified strain 
associations of E. coli with CTX-M type ESBLs production. E. coli ST131 and to a lesser extent 
ST10 clonal complex which were found to be associated with the production of a most 
widespread and prevalent CTX-M-15 globally (Pitout, 2012a). Like the ESBLs, plasmid-
mediated AmpC also were reported in E. coli from community onset urinary tract infection 
(UTI) (Pitout, 2012a). CMY-2 is the most commonly encountered AmpC type β-lactamase 
among the Enterobacteriaceae globally (Pitout, 2012a). In Canada, a study conducted in the 
Calgary Health Region, found that the CMY-2 type enzyme was the most prevalent type AmpC 
β-lactamases in E. coli from patients with UTI (Pitout, 2012a). In Canadian hospitals, 
surveillance studies have shown that 13.5% of 232 cefoxitin resistant isolates possessed CMY-2 
(Mulvey et al., 2005). Since the mid 2000s, the emergence of carbapenemase producers has been 
described in Canada. Though low percentage of carbapenem-resistant Enterobacteriaceae (CRE) 
and carbapenem-resistant organisms (CRO) were reported in Canadian hospital patients in the 
year 2010 - 2014, however, there was an increasing trend of CRE  (Public Health Agency of 
Canada, 2016). KPC was mostly encountered CRE followed by NDM-1 and Oxa-48 (Public 
Health Agency of Canada, 2016). 
1.2.2 Broad-spectrum β-lactamases in agricultural animal isolates 
Food producing animals are a potential source of antimicrobial resistance in community. 
Cattle, pigs and chickens are considered as major food animal species. There is a high possibility 
of bacterial contamination during slaughter process of these animals. Different countries have 
implemented surveillance programs to monitor antimicrobial resistance in healthy animals to 
assess the potential zoonotic risk. ESBL producing E. coli is a growing concern in food and food 
producing animals globally (Bhoomika et al., 2016). A variety of ESBLs including: CTX-M-1, 
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CTX-M-2, CTX-M-8, CTX-M-14 and CTX-M-15 have been identified from poultry in different 
regions while CTX-M-1 is the predominant ESBL in agricultural animals (Belmar Campos et al., 
2014; Börjesson et al., 2013). A variety of pAmpC including CMY-2, DHA-1 and ACC-1 have 
been identified in E. coli from chickens, although CMY-2 is the most common (Börjesson et al., 
2013; Reuland et al., 2014). In Canada, Canadian Integrated Program for Antimicrobial 
Resistance Surveillance (CIPARS) is monitoring AMR in food producing animals in national 
level (Government of Canada, 2015a). CIPARS findings showed isolates from chicken were 
resistance towards 3GC and amoxillin-clavulanic acid, which suggests that Canadian chicken 
might harbor broad-spectrum β-lactamase genes (Government of Canada, 2015b). One study in 
Canada found CMY-2 as predominant β-lactamase type in chicken meat which possessed 
resistance to 3GC (Sheikh et al., 2012). Comparing with other part of the world, there is very 
limited data on β-lactamase producing organisms from agricultural animals in Canada. 
1.2.3 Antimicrobial resistance studies in Canada 
The Public Health Agency of Canada (PHAC) plays a major role in antimicrobial 
resistance surveillance studies in Canada. The PHAC select certain bacteria of high importance 
in their AMR studies from the list of 138 disease causing infectious pathogen which are posing 
resistant throughout the world  (Public Health Agency of Canada, 2016). In health-care settings, 
PHAC surveillance systems currently monitor resistance in Clostridium difficile, carbapenem-
resistant organisms (CRO) including carbapenem-resistant Enterobacteriaceae (CRE), 
methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci 
(VRE). In community settings, PHAC’s surveillance systems monitors Streptococcus 
pneumoniae, Group A Streptococcus (GAS), Neisseria gonorrhoeae and Mycobacterium 
tuberculosis (Public Health Agency of Canada, 2016). PHAC also monitors zoonotic and 
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foodborne organisms including E. coli, Salmonella and Campylobacter from human clinical 
cases, retail food, animals at slaughter, on farm, and from veterinary diagnostic labs through 
CIPARS (Public Health Agency of Canada, 2016). CIPARS performs surveillance of 
antimicrobial use in agriculture and the presence of antimicrobial resistant organisms. They 
collect data of antimicrobial use in human and animal population, as well as select bacteria 
isolated from human and animal diagnostic submissions (Government of Canada, 2015a). Retail 
food samples, including fresh raw turkey, beef, pork, and chicken are included to provide 
exposure estimates close to the point of consumption (Government of Canada, 2015a). At the 
abattoir level, caeca of beef cattle, broiler chickens and pigs are sampled in order to reflect 
transmission of monitored antimicrobial resistance through the food chain prior to entry into the 
retail segment (Government of Canada, 2015a). On-farm surveillance monitors microbial 
resistance in bacteria from fecal samples from grower-finisher pigs and broiler chickens to 
provide surveillance data at the production level and to enable estimation of associations 
between husbandry practices, including antimicrobial use, and antimicrobial resistance 
(Government of Canada, 2015a). Data generated from animal, food and human isolates are 
analyzed to identify temporal changes in antimicrobial resistance and use annually (Government 
of Canada, 2015a). 
 
1.3 The Canadian chicken industry 
1.3.1 The quota system and production flows 
In Canada, the poultry industry is well regulated by national bodies and provincial level 
organizations to ensure Canadians have access to safe poultry products. In Ontario, the Ministry 
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of Agriculture, Food Safety and Rural Affairs (OMAFRA), Chicken Farmers of Canada (CFC), 
Chicken Farmers of Ontario (CFO) are the key regulatory organizations. OMAFRA is 
responsible for regulating provincially inspected slaughter facilities. CFC is the national 
regulatory body for chicken industry in Canada. CFC determines the national supply of chicken 
based on the Canadian market requirements. CFC also determines the provincial production rate 
based on the provincial commodity groups demand and market requirements (Chicken Farmers 
of Canada, 2016a). CFO determine the number of allocation demand within the province to the 
national agency after consulting with industry stakeholders (OMAFRA, 2014).  Ontario’s quota 
system is part of the supply managed system across Canada for the broiler chicken industry. 
Quota is a license issued by CFO to produce and market chicken in the province. It limits the 
farmer to produce and market a certain amount of chicken meat within a specific time period set 
by CFO. A unit of quota is equal to 13 kilograms of chicken production per annum, and quota 
holding farmers must have at least 14,000 units of quota equating to approximately 182,000 
kilograms of chicken production per year (Chicken Farmers of Ontario, 2016a). In 2015, there 
were 36,450,014 quota units in Ontario representing approximately 489 million kilos of chicken. 
Until 2014, farmers without quota were permitted to produce no more than 300 chickens per year 
in Ontario. Non-quota holding farms are often described as backyard or small flock producers 
(Chicken Farmers of Ontario, 2016a). 
1.3.2 Overview of small scale vs. industrial production 
Canada’s poultry industry is growing and it produced chicken products that were worth 
$2.4 billion in 2015 and contributed $6.8 billion to Canada’s Gross Domestic Product (Chicken 
Farmers of Canada, 2016b; Government of Canada, 2016a). There were 2690 regulated chicken 
producers in Canada which produced 1.1 billion kilograms of chicken in 2015 (Government of 
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Canada, 2016a). The per person consumption of chicken meat has increased in 2015, while pork 
and beef consumption have declined (Government of Canada, 2016b). Canada also exported a 
small number of chicks (5.8 million) to 9 different countries and 133.2 million kilograms of 
chicken meat products to 63 different countries in 2015 (Government of Canada, 2016b). The 
United States is the largest export market for Canadian chicken. As Canada’s most populated 
province with a population of 13.9 million (Government of Canada, 2016c), Ontario is also the 
largest chicken producer in Canada with 1,155 chicken farmers and 42 processors, the Ontario 
chicken industry contributed $2.2 billion to Canada’s GDP (Chicken Farmers of Canada, 2016b). 
Besides large-scale commercial farming, there is an increased demand for local or small-scale 
chicken in Canada. In prior regulation, non-quota holding farmers were not allowed to have more 
than 300 birds annually. However, to meet the local demands, Canadian provinces have launched 
different schemes which will allow small, independent, locally based farmers to have their small-
scale chicken farms. In Ontario, artisanal chicken program is one of them which will allow the 
farmers to grow between 600 to 3000 chickens per year without holding any quota. Until June 
2016, there were total 103 artisanal chicken farmers with average 1564 chickens per farm 
(Chicken Farmers of Ontario, 2016b). 
1.3.3 Provincially vs. federally regulated abattoirs 
There are two regulatory schemes for abattoir inspection in Canada, federal and 
provincial. Federally inspected abattoirs have a large slaughter capacity and process 
approximately 95% of food producing animals (Government of Canada, 2015a). Meats for inter-
provincial consumption or export must have to pass though federally inspected abattoirs. The 
meat inspection of federally inspected abattoirs is performed by Canadian Food Inspection 
Agency (CFIA) (Government of Canada, 2013). In Ontario, most of the large commercial broiler 
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chickens are slaughtered in federally inspected abattoirs, while smallholder or “backyard” flocks 
typically raised by small-scale producers are slaughtered in provincially inspected abattoirs. 
Current resistance surveillance done by CIPARS focuses only on birds passing through federally 
inspected abattoirs, birds processed in provincially inspected abattoirs are not represented in 
CIPARS sampling (OMAFRA, 2016). 
 
1.4 Zoonotic and foodborne transmission of Escherichia coli from chickens into 
people 
Zoonosis is a term used to describe those diseases which transmitted to human from 
animals. Those pathogens transferred by contaminated food are sub-classified as foodborne. 
Most E. coli strains are colonizers which are part of the gastrointestinal microbiota of healthy 
individuals (Canny and McCormick, 2008). There are some opportunistic and pathogenic E. coli 
which can cause a variety of illnesses in healthy human and animals (Kaper et al., 2004). E. coli 
are often grouped into one of six pathotype categories: enteropathogenic, enterotoxigenic, 
enterohemorrhagic, enteroinvasive, enteroaggregative and diffuse-adhering. While extra-
intestinal pathogenic E. coli (ExPEC) can be categorized as uropathogenic and meningitis 
associated (Hammerum and Heuer, 2009; Kaper et al., 2004; Manges and Johnson, 2012). Extra-
intestinal pathogenic E. coli (ExPEC) are responsible for most community and hospital onset 
human infections such as urinary tract and bloodstream infections, sepsis (Manges and Johnson, 
2012). Avian pathogenic E. coli is associated with extra-intestinal infections in chickens, turkey 
and other poultry species including pericarditis, airsaculitis, polyserositis and septicemia (Dho-
Moulin and Fairbrother, 1999; Kaper et al., 2004). Genes coding for virulence factors of these 
pathogenic strains are often located in the chromosome on pathogenicity islands (PAI) which are 
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large genomic regions not found in commensals. Interestingly, these pathogenic strains can 
acquire additional factors which are encoded by mobile genetic elements such as plasmids, 
bacteriophages and transposons, thus can be transmitted to other bacteria easily (Kaper et al., 
2004). Food animals and retail meat products are a potential reservoir for human ExPEC 
infection. Compared with beef or pork, chicken meat has been found to be a source of ExEPC 
which are more genetically similar to isolates causing UTIs in human (Bergeron et al., 2012; 
Manges and Johnson, 2012). Different studies have found an association between antimicrobial 
use and the presence of resistance in animals (Agersø et al., 2012; Cohen Stuart et al., 2012; 
Lowrance et al., 2007). A significant relationship between incidence of ceftiofur-resistant 
Salmonella enterica serovar Heidelberg in humans and retail chickens and the use of ceftiofur in 
chicken was identified in Canada demonstrating the link between animals and people and 
highlighting the role of chickens specifically (Dutil et al., 2010). Similarly, in the Netherlands, 
the predominant indistinguishable ESBL genes have been found in chicken and human rectal 
swabs specimen (Overdevest et al., 2011). Therefore, we argue that chicken meat a plausible 
source of resistance in humans. 
 
1.5 Using Escherichia coli as a resistance surveillance target 
1.5.1 Strategies for representative sampling 
Resistance surveillance programs around the world such as CIPARS in Canada, NARMS 
in USA, DANMAP in Denmark, JVARM in Japan have targeted E. coli because of its usefulness 
as an indicator organism for antimicrobial resistance in other taxa of the gut microbiota (Franklin 
et al., 2001; Government of Canada, 2015a; Morrison and Rubin, 2015; Zhao et al., 2012). 
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Furthermore, the relative case of E. coli recovery (97-100%) from chicken caeca makes it an 
ideal target for resistance surveillance compared to Salmonella or Campylobacter for which 
recovery rates (13-28%) are much lower (Government of Canada, 2015b). Testing E. coli is 
therefore an efficient means to an estimate of resistance prevalence. Furthermore E. coli can be 
zoonotic and antimicrobial resistant E. coli isolates colonizing and infecting people have been 
shown to be an important food borne zoonoses which may result in urinary tract and bloodstream 
infections therefore having a direct impact on human health (Bergeron et al., 2012; Kluytmans et 
al., 2013; Vincent et al., 2010). Therefore, E. coli could be a good choice of organism for starting 
resistant surveillance in chicken population. 
1.5.2 Sample collection and processing strategies 
Effective resistance surveillance requires the development of sampling strategies which 
balance the relationship between cost effectiveness, feasibility, and statistical plausibility 
(Benedict et al., 2013; Yamamoto et al., 2014). The ‘single sample per farm’ strategy 
recommended by European Food Safety Authority (EFSA) has been found to be the most 
sensitive sampling strategy for detecting resistant organism at the population level (Yamamoto et 
al., 2014). This strategy has been used by surveillance programs in different countries including 
Canada, Japan, Sweden, Denmark and Netherlands (Yamamoto et al., 2014). Which materials 
should be targeted as samples depend on several factors such as whether the study targets retail 
meat, abattoirs or animals on farm.  Collecting caeca content will be a good choice as it helps to 
avoid misinterpretation related to cross-contamination and to better reflect antimicrobial 
resistance in bacteria that originated on the farm (Government of Canada, 2015a). In the majority 
of chicken microbiota studies, ceca used as a sample for its productivity, health and wellbeing of 
chicken, however, it requires sacrificing the birds (Stanley et al., 2015). While fecal sampling is 
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more convenient comparing with cecal content as it allows using the same bird for repeated 
sampling without killing (Stanley et al., 2015). However, fecal samples are susceptible for 
environmental contamination. 
1.5.2.1 Culture and identification of Escherichia coli 
Propagation and identification of E. coli can be done by using bacterial culture media and 
different biochemical tests. MacConkey agar is commonly used for the isolation of E. coli in 
clinical laboratory settings. MacConkey agar contains lactose as fermentable sugar and neutral 
red as pH indicator. It also contains bile salts and crystal violet as inhibitors which suppress the 
growth of Gram-positive bacteria. On MacConkey agar E. coli produce deep red colonies as the 
organism is lactose-positive, and fermentation of this sugar will cause the medium's pH to drop, 
leading to darkening of the medium (Markey et al., 2013). Eosin methylene blue (EMB) agar is 
occasionally used in diagnostic laboratories for detection of E. coli. This agar contains eosin and 
methylene blue as pH indicator, sucrose and lactose as carbohydrate source. The pH indicator 
dyes turn into dark purple color at low pH and suppresses the growth of Gram-positive bacteria 
partially. Growth of E. coli on EMB agar produces black colonies with a greenish-black metallic 
sheen (Markey et al., 2013). Besides that, different selective media are used to detect specific 
bacterial strains such as CHROMagar ESBL which can be helpful to identify ESBL producing E. 
coli. Following a presumptive identification of E. coli from a differential media, the biochemical 
properties of an organism can be useful for identification. On Table 1.2, some important 
characteristics for differentiating members of Enterobacteriaceae family are included. 
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Table 1.2: Biochemical properties of clinically important members of Enterobacteriaceae 
family 
 ID MR VP Cit Ure PD HS Mot GL 
E. coli + + _ _ _ _ _ + _ 
K. pneumonia _ _ + + + _ _ _ _ 
S. enterica _ + _ + _ _ _ + _ 
  
ID - Indole production, MR - Methyl red, VP - Voges-Proskauer, Cit - Citrate, Ure - Urease, PD 
- Phenylalanine deaminase, HS - Hydrogen sulphide, Mot - Motility, GL - Gelatin liquefaction; 
Table adapted from (Markey et al., 2013). 
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1.5.3 Detection and characterization of antimicrobial resistance 
1.5.3.1 Phenotypic antimicrobial susceptibility testing 
The goal of antimicrobial susceptibility testing is to determine whether an isolate is 
resistant to drugs of interest. Commonly used susceptibility testing methods include disk 
diffusion, gradient strip, agar dilution and broth microdilution. Test results with minimum 
inhibitory concentration (MIC) value will give quantitative data where interpreting zone 
diameters will give categorical data. The disk diffusion test yields a categorical description while 
all others are quantitative (Jorgensen and Ferraro, 2009). Disk diffusion and broth microdilution 
are the two methods which are commonly used in veterinary medicine as well as resistance 
surveillance programs (Benedict et al., 2013; Brooks et al., 2003). 
Disk diffusion testing: This method also known as Kirby-Bauer antibiotic testing was 
first described by Bauer, Kirby, Sherris and Turck in 1966 (Bauer et al., 1966). Antibiotic 
impregnated discs are placed on agar plates inoculated with the test bacterium. Antimicrobial 
agent will diffuse and create a zone of diffusion which will inhibit the growth of susceptible 
bacteria (Markey et al., 2013). Based on the size of the zone diameter, to the test can be 
interpreted using standardized guidelines to determine whether the organism is resistant or 
susceptible. The first step is to prepare a bacterial suspension in saline or deionized water. The 
inoculum turbidity must be matched with 0.5 McFarland standard, which corresponds to 
approximately 1.5 × 108 CFU/ml. A lawn of inoculum is streaked out evenly onto the surface of 
muller-hinton agar (MHA) plate. Typically, up to 12 antimicrobial disks can be placed on a 
single plate at a time. Following inoculation, plates are inverted and incubated at 35°C for 16-18 
hours. The zones of bacterial growth inhibition around each drug are measured to the nearest 
millimeter using a ruler or slide-calipers (Figure 1.2), and the size of the zone of inhibition can 
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then be interpreted using Clinical and Laboratory Standards Institute (CLSI) or EUCAST criteria 
(Coyle, 2005; Jorgensen and Ferraro, 2009). This method is simple, inexpensive, allows for 
testing customized drug panels but only provides categorical data which is a key drawback 
(Coyle, 2005). 
Gradient Strip Test: Gradient strips (such as E-tests) are commercially available thin 
inert non-porous plastic strips impregnated with predefined antimicrobial gradient underside and 
the concentration scale is on the surface of it (Jorgensen and Ferraro, 2009). In brief, bacterial 
inoculum preparation and plating on agar media as described above. Typically, 4-6 strips can be 
placed on to a 150-mm plate in a radical fashion. During this incubation period, there is an 
establishment of antimicrobial gradient concentration around the strip because of immediate 
release of the drug. Following overnight incubation, the bacterial growth is visible and the tests 
are read by viewing a tear drop shaped inhibitory zone along the strip (Figure 1.3). The MIC is 
determined where the lower part of the inhibitory zone intersects with the gradient strip 
(Jorgensen and Ferraro, 2009). 
Broth microdilution: Broth microdilution is a widely used test to determine 
antimicrobial MIC (Coyle, 2005). In this method, test bacterium is inoculated on a series of tubes 
containing antibiotic on different concentration. The highest concentration which will inhibit the 
growth of an organism is defined as the MIC (Markey et al., 2013). Commercially prepared tests 
(such as Sensititre) are available in 96 well microtiter plate format contains multiple doubling 
dilutions of a variety of antimicrobial agents. Each plate also contains positive and negative 
controls (Coyle, 2005; Jorgensen and Ferraro, 2009). In this test, MICs are determined using a 
manual or automated viewing device by observing the lowest concentration of antimicrobial 
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agent which completely inhibits growth of the organism (Figure 1.4) (Coyle, 2005; Jorgensen 
and Ferraro, 2009).  
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Figure 1.2: Kirby-Bauer disk diffusion test. 
 
Figure 1.3: Antimicrobial gradient strips and tear drop shaped inhibitory zones. 
 
Figure 1.4: Broth micro-dilution antimicrobial susceptibility test.  
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1.5.3.2 Identification of resistance genes 
The polymerase chain reaction (PCR) is a technique to amplify specific DNA sequences 
and can be applied to detect bacterial resistance genes. This technique produces millions of 
copies of target sequence of resistance gene DNA within a short time using a heat stable DNA 
polymerase (Taq) to mimic the natural process of DNA replication. Taq polymerase uses existing 
single-stranded DNA as a template and attaches dNTPs into the growing strand of DNA to make 
complimentary copy of DNA template (Bartlett and Stirling, 2003). Typically, PCR consists of 
20 - 40 cycles of the three basic steps; denaturation, annealing and elongation (Viljoen et al., 
2005). This technique can be applied to identify ESBL, AmpC or carbapenemase genes from 
resistant isolates in order to understand if there are epidemiologically resistant genes present. 
 Sequencing of PCR amplicons is commonly done to identify the allele of amplified loci 
and identify polymorphisms. The dideoxy method of DNA sequencing (Sanger sequencing) is 
often employed for amplicon sequencing. This method utilizes nucleotide triphosphates called 
dideoxynucleoside triphosphates (ddNTP) which substitute for deoxynucleotides at random 
positions during polymerization resulting in termination of DNA synthesis in a base-specific 
manner. Four PCR reactions are performed where each contains one dideoxynucleoside 
triphosphate (ddNTP) analog in addition to the four nucleotides (ATP, CTP, GTP or TTP) to 
terminate at A, G, C and T residues (Sanger et al., 1977). Each of these four sets will create 
fragments which will be resolved by electrophoresis in four separate lanes or can be visualized 
fluorescently using labeled ddNTP. 
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1.5.4 Molecular epidemiological techniques 
1.5.4.1 Pulsed-field gel electrophoresis (PFGE) 
Until the introduction of whole genome sequencing, pulsed-field gel electrophoresis 
(PFGE) has considered as the gold standard for comparing bacterial relatedness (Goering, 2010; 
Jordan and Dalmasso, 2015). PFGE is a molecular epidemiological tool used to identify and 
characterize outbreaks of food-borne disease or antimicrobial resistant organisms. PFGE is 
versatile, reproducible, relatively inexpensive, highly discriminatory and results in good 
epidemiological concordance for many pathogens (Jordan and Dalmasso, 2015). This method 
was first used for yeast Saccharomyces cerevisiae in 1980’s for genome mapping by separating 
the large DNA fragments (Schwartz and Cantor, 1984). By the mid 1990’s, PFGE was employed 
in surveillance studies to detection and identify disease clusters (Jordan and Dalmasso, 2015). In 
1996, the US Center for Disease Control and Prevention (CDC) introduced PulseNet, a 
laboratory network utilizing PFGE based DNA fingerprinting targeting food-borne pathogens. 
Currently, 82 countries participate in the PulseNet system. PFGE is limited by the requirement 
for specialized laboratory equipment and trained staff, time consuming, less discriminating 
ability than whole genome sequencing (CDC, 2016a). In brief, this method involves embedding 
the bacterial DNA in agarose plug, digestion with restriction enzymes and resolution of 
fragments to reveal banding patterns. Banding pattern are analyzed using computer assisted 
analysis of digitized images. Isolates can be defined as indistinguishable, closely related, 
possibly related and unrelated based on their independent genetic event and number of fragment 
differences. Isolates with no fragment differences would be called indistinguishable while those 
differing by 2-3 bands is closely related. Isolates with 4-6 band differences are possibly related. 
If less then 50% of the isolates bands match with outbreak strain then that isolates are considered 
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as non-related strain (Tenover et al., 1995). Groups of isolates with 80% or greater relatedness 
can be defined as clusters which corresponds to the criteria of the “possibly related” (4 to 6 
bands difference) (Peirano et al., 2012). 
1.5.4.2 Multi-locus sequence typing (MLST) 
MLST is a nucleotide sequence based technique used for unambiguous characterization 
of bacteria. MLST schemes have been developed for a variety of bacteria to identify clonal 
groups and large-scale phylogenetic relatedness. This technique targets multiple protein coding 
housekeeping genes found in all isolates of a particular species (Wirth et al., 2006). Because 
housekeeping genes serve metabolic functions, they are under stabilizing selection pressure; 
changes in the amino acid sequence of these proteins occur slowly and therefore provide reliable 
insight into the relatedness of isolates (Bergeron et al., 2012; Johnson and Russo, 2005; Maiden 
et al., 1998). Most MLST schemes include 300-700 bp regions of seven housekeeping genes 
from the core genome are selected, amplified and sequenced (Cooper and Fel, 2004). The 
sequence of gene is given a distinct allele number using a centralized database, unique allele 
numbers are assigned whether they differ by a single nucleotide or by multiple polymorphisms 
(Urwin and Maiden, 2003). The alleles of each of the seven housing keeping genes of each 
isolates are combined into an allelic profile and assigned a sequence type (ST). Sequence types 
can be grouped together into clonal complexes comprising closely related strains. MLST is a 
good typing technique comparing with other typing methods as it can detect the changes on 
nucleotide sequences of bacterial DNA, highly reproducible, does not require any sophisticated 
instruments or expensive reagents, it’s a conventional PCR based techniques. Most importantly, 
MLST data are analyzed based on centralized database yielding portable data allowing 
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comparisons the ST of an individual isolate to the global database (Belén et al., 2009; Wirth et 
al., 2006).  
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Objectives 
▪ To determine if broad spectrum β-lactamase genes are present in E. coli from chickens 
raised in small flocks in Ontario, Canada.  
▪ To determine the relatedness and sequence types of E. coli isolates from chickens raised 
in small-scale flocks. 
▪ To compare the use of selective and non-selective media for the detection of β-lactamase 
producing E. coli in chickens coming from Canadian large commercial flocks. 
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2.1 Abstract 
Meat producing animals including chicken play an important role in dissemination of 
antimicrobial resistant bacteria to the community. In Canada, there is a lack of data about the 
prevalence of antimicrobial resistance in bacteria from chickens raised by small producers and 
passing through provincially inspected abattoirs. Therefore, this study was conducted to detect 
the presence of broad-spectrum β-lactamase producing E. coli and compare their relatedness with 
susceptible strains from chickens raised in small flocks in Ontario. A total of 1025 cecal samples 
(205 flocks, 5 birds each) were collected at provincially inspected abattoirs. A total of 99 3rd 
generation cephalosporin resistant isolates were identified by broth micro-dilution using 
Sensititre®. All these resistant isolates were screened for ESBL or AmpC β-lactamase by PCR. 
Finally, the 99 β-lactamase producers and 162 randomly selected susceptible E. coli isolates 
collected from the same 205 flocks were characterized by pulsed-field gel electrophoresis 
(PFGE) to determine their relatedness. To identify the sequence type, 24 isolates were 
characterized using MLST. A total of 55 ESBL producing strains were isolated from 26/205 
(12.7%) of the flocks sampled while 39 AmpC β-lactamases were from 31 (15.1%) flocks. CTX-
M-1 and CMY-2 were the most prevalent ESBL and AmpC enzyme respectively. While the 
majority of isolates were unrelated, 9 clusters (at least 3 isolates ≥85% similar) were identified 
by PFGE. Characterization of isolates by multi-locus sequence typing identified 16 different STs 
and 4 different ST clonal complexes. ST10 clonal complex was observed in both cluster and non-
cluster forming isolates. Our results suggest that chickens raised in small flocks in Ontario may 
be a source of E. coli resistant to clinically relevant drugs, and that the dissemination of this 
resistance in chickens is most likely associated with the spread of plasmids rather than particular 
E. coli clones.  
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2.2 Introduction 
Antimicrobial resistance is an emerging problem throughout the world including Canada. 
Particularly resistance associated with Gram-negative bacteria has increased globally (Hsu et al., 
2010). Serious hospital acquired and community onset bacterial infections in humans including 
urinary tract infection are commonly caused by E. coli (Livermore, 1998; Paterson, 2006). In 
chickens, extra-intestinal infections with E. coli fall into syndrome “colibacilllosis” which 
describes a constellation of syndromes affecting chickens including airsacculitis, cellulitis, 
pericarditis, perihepatitis and respiratory distress (Kemmett et al., 2013). β-lactam antibiotics are 
important drugs in treating infections caused by E. coli, however, β-lactamase are the bacterial 
resistance enzymes which hydrolyse and make these antibiotics inactive (Livermore and 
Woodford, 2006).  
Isolates of Enterobacteriaceae possessing ESBL and AmpC β-lactamases are increasingly 
common in human as well as animal population including chicken (Pitout, 2012b). Current data 
indicate that CTX-M β-lactamases are increasing and are the most prevalent ESBL type. In 
Europe chicken E. coli isolates have been extensively studied; TEM-52, CTX-M-14 and CTX-
M-32 types ESBLs enzymes were detected in cefotaxime-resistant E. coli obtained from broilers 
in Portugal (Costa et al., 2009), while CTX-M-1, CTX-M-32 and SHV-12 types were found in 
Italy (Bortolaia et al., 2010). In Switzerland, CTX-M-1, SHV-12 and TEM-52 ESBLs were 
detected in E. coli strains recovered from faecal samples from healthy chickens (Geser et al., 
2012a). The high prevalence of ESBLs and pAmpC producing E. coli in food producing animals 
has also been found to be common in Europe. In Canada, data from surveillance programs such 
as Canadian Integrated Program for Antimicrobial Resistance Surveillance (CIPARS) findings 
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suggest that Canada may also have a high prevalence of broad-spectrum β-lactamase producing 
organisms. 
A potential hazard resulting from the selection and spread of antimicrobial resistance in 
food animal production is the transmission of resistant bacteria or plasmids carrying resistance 
genes to humans via contact with animals or contaminated food (Sabaté et al., 2008). The 
relationship between in vitro resistance to β-lactams and ceftiofur usage has been observed in a 
number of food animal species including chicken (Agersø et al., 2012; Cohen Stuart et al., 2012; 
Lowrance et al., 2007). A positive correlation between the incidence of ceftiofur resistant 
organisms in human and in chickens and use of ceftiofur in hatcheries were observed in Canada 
(Dutil et al., 2010). These Canadian findings demonstrated the link between antimicrobial usage 
in chickens and resistant organisms in people (Dutil et al., 2010). This evidence suggests that 
chicken meat is a plausible source of resistance in humans in Canada. 
In Canada, the CIPARS abattoir program, exclusively samples chickens processed in 
federally inspected abattoirs, which process the vast majority of food animals (Government of 
Canada, 2015a). These birds originate from large producers that supply uniform chickens (age, 
weight and breed) using standard husbandry. Birds which are slaughtered outside of the federal 
system and are processed in provincially inspected facilities are minor contributors to overall 
production in Canada (Government of Canada, 2016d). These birds may be heterogeneous in 
terms of age, weight and breed and include chickens raised on small, non-quota farms which 
until 2014 produced <300 birds/year. It should be noted that the increasing popularity of local 
food movements, farmer’s market, and farm gate sales may result in an increase in the proportion 
of chickens slaughtered in provincial facilities over time. Because the microbiota changes with 
age, including changes in resistance and virulence in E. coli, chickens passing through 
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provincially inspected facilities may be colonized with E. coli populations with different 
resistance profiles than those captured by CIPARS (Kemmett et al., 2013; Ozaki et al., 2011). 
While the use of antimicrobials on any given chicken farm is ill-defined (Agunos et al., 2012), 
use by small producers who may have poorer bio-security and therefore have a higher burden of 
disease, house other animal species on unspecialized farms, or that have less consultation with 
poultry veterinarian is even less predictable. Therefore, although chickens from provincially 
inspected facilities account for a small percentage of the chicken consumed in Ontario, they may 
have a higher prevalence of resistant E. coli and therefore a disproportionately high impact on 
human health.  
As the ESBLs are increasingly common among E. coli isolated from community settings 
(Woerther et al., 2013), determining the presence of these among chicken E. coli is important to 
better understand the epidemiology of resistance. Furthermore, finding resistant E. coli strain 
type in chicken will help to assess the risk of zoonotic transmission of resistance determinants. 
Overall the objective of this study to determine and characterize the broad-spectrum β-lactamase 
producing E. coli in chickens originating from small flocks passing through provincially 
inspected abattoirs in Southern Ontario, Canada. 
 
2.3 Method and Materials  
2.3.1 Study design 
This study was conducted to identify broad-spectrum β-lactamase encoding E. coli and 
determine the clonal relationship of these isolates. As human resistant pandemic clone (E. coli 
ST131) has been identified health care settings, so we also investigated whether chickens from 
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Canadian small-scale flocks were harboring the same. This was a collaborative study with 
researchers at the University of Guelph. Sample collection, isolation and identification of 
bacteria and antimicrobial susceptibility testing was performed at the University of Guelph. E. 
coli isolates were sent to the University of Saskatchewan where additional molecular 
characterization was done. 
2.3.2 Samples for Molecular characterization 
Cecal samples were collected at slaughter from 1025 chickens originating from 205 small 
flocks (5/flock) at provincially inspected abattoirs in southern Ontario. Samples were selectively 
cultured for E. coli on MacConkey and CHROMagar ESBL, the antimicrobial susceptibility of 
isolates was determined by broth micro-dilution. All 3rd Generation Cephalosporin (3GC) 
resistant and a subset of susceptible isolates were sent on broth packed in cooling box to the 
University of Saskatchewan for molecular characterization. 
2.3.3 Detection of ESBLs, AmpC β-lactamase and class I integrons using PCR 
A total of 99 isolates resistant to 3GC were subjected to PCR to detect ESBL and AmpC 
encoding genes. Bacterial DNA was crudely extracted from the isolates by boiling (boil-prep). 
Previously published primers of CTX-M-U, CTX-M-G-1 and CMY-2 gene were used to detect 
ESBL and AmpC genes as well as class I integrons (Table 2.1). PCR reactions were carried out 
in 25µL volumes including 24µL of master-mix and 1μL of boil prep DNA template. In each set 
of reactions, positive and negative controls were included. Thermocycler conditions were as 
follows: initial denaturation at 94°C for 6 mins followed by 35 cycles of: denaturation at 94°C 
for 1 min, annealing at 61°C (CTX-M-U, CTX-M-G1)/68°C (CMY-2) for 1 min, elongation at 
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72°C for 1 min followed by final extension at 72°C for 10 mins. For class I integrons, touch-
down PCR was performed with the following cycling conditions: 94°C for 6 mins, 22 cycles of 
94°C for 1 min, 78°C -1°C for 1 min, 72°C for 1 min, 15 cycles of 94°C 1 min, 56°C -1°C for 1 
min, 72°C for 1 min with a final extension at 72°C for 10 mins. Amplicons were resolved by 
electrophoresis using 1% agarose gel at 110 volts for 30 minutes. Gels were then visualized 
under UV light using the AlphaImager® HP (Fisher Scientific, ON, Canada).  
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Table 2.1: PCR primers used for detecting ESBL, AmpC β-lactamase and class I integron 
Primer Name Primer Sequence References 
CTXM-U 
5’ -ATGTGCAGYACCAGTAARGTKATGGC- 3’ 
(Munday et al., 2004) 
5’ -TGGGTRAARTARGTSACCAGAAYCAGCGG- 3’ 
CTXM-G1 
5’ -GTTGTTAATTCGTCTCTTCC- 3’ 
(Pitout et al., 2004) 
5’ -AGTTTCCCCATTCCGTTTC- 3’ 
CMY-2 
5’ -ATGATGAAAAAATCGTTATGCTGC- 3’ (Kruger et al., 2004) 
5’ -GCTTTTCAAGAATGCGCCAGG- 3’ (Hasman et al., 2005) 
Class I integron 
5’ -GGCATCCAAGCAGCAAG- 3’ 
(Pellegrini et al., 2011) 
5’ -AAAGCAGACTTGACCTGA- 3’ 
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2.3.4 PCR amplicon purification and nucleotide sequencing 
PCR products were purified using EZ-10 Spin Column PCR purification kit (Bio Basic 
Canada Inc., ON, Canada) and DNA was quantified by spectrophotometrically (NanoDrop™ 
1000). Purified DNA with ~1.8 ratio of absorbance at 260 nm and 280 nm and 2.0 - 2.2 of 
260/230 values were considered to have sufficiently high quality for sequencing. DNA solutions 
with a concentration of 10 - 50ng/μL were then sequenced by a commercial lab using the 
amplification primers. DNA sequences were assembled, edited and analyzed using gap4 and 
Pregap4 software’s (part of Staden Package). The identity of contigs generated from sequence 
analysis was determined by comparison to a set of reference sequences listed on Lahey database 
(www.lahey.org) using CLC sequence viewer version 7 (Qiagen Inc., CA, USA).  
2.3.5 Pulsed-field gel electrophoresis  
261 isolates were selected for PFGE including all 99 3GC resistant isolates and 162 
susceptible E. coli. PFGE was performed as described by PulseNet protocol using the CHEF-
DRIII system (Bio-Rad Laboratories Ltd., ON, Canada) (CDC, 2016b). In brief, isolates from 
frozen stock culture (-80°C) were plated on blood agar and incubated overnight at 35°C. 
Colonies were suspended in 2ml of Gram-negative cell suspension broth and adjusted to 3 
McFarland using a densitometer. 250μl of cell suspension were dispensed into a 1.5 ml micro-
centrifuge tube and 11.4μl of proteinase-K added into it and then mixed with 227μl of melted 
(56°C) 1% SeaKem Gold Agarose (Lonza Rockland Inc., ME, USA) and quickly casted into the 
plug mold. Plugs were kept at room temperature until solidified. To begin the cell digestion, 
plugs were dispensed in 5ml Gram-negative cell lysis buffer containing 25μl of proteinase-K and 
incubated in water bath for ≥ 2 h at 56°C. After incubation, cell lysis buffer was decanted and 
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plugs were washed with distilled water for 15 minutes using a shaker with shaking at ~200rpm. 
The water was decanted, and the plugs were then washed 3 times with Gram-negative TE buffer 
for 15 mins each using a shaker with shaking at ~200rpm. Finally, plugs were stored in TE 
buffer at 4°C until used. 1/3 of each plug was subjected to restriction digest. For digestion, plugs 
were transferred into a 50ml polypropylene conical tubes containing 200μl of 1x equilibration 
buffer (10x buffer and BSA) and incubated for 10 minutes at 37°C. The equilibration buffer was 
then aspirated, and 200μl enzyme digestion solution (XbaI, 10x buffer and BSA) was then added; 
plugs were then incubated for ≥ 2 hours at 37°C. Following digestion, plugs were loaded in 1% 
agarose gel. The XbaI digested DNA fragments were separated by electrophoresis in 0.5X 
electrophoresis TBE buffer at 14°C for 20h on CHEF-DRIII electrophoresis system with an 
initial switch time of 2.16 s, a final switch time of 54.17 s, a 120° switch angle, and a gradient of 
6.0 V/cm. Salmonella enterica serotype Branderup was used as reference ladder. Following 
electrophoresis, gels were stained with 600ml of distilled water containing 20μl of ethidium 
bromide for 20 mins and de-stained with 600ml of distilled water for 20 mins. DNA fragments 
were visualized with AlphaImager® HP (Fisher Scientific, ON, Canada) and photographed. The 
relatedness of all isolates was determined using Gel Compare II (Applied Maths Inc., TX, USA) 
based on Tenover criteria (Tenover et al., 1995). At least 3 isolates with ≥85% band similarity 
were defined as cluster (Tenover et al., 1995; Thorsteinsdottir et al., 2010). Cluster analysis was 
done using the Dice co-efficient with unweighted pair group method using arithmetic averages 
(UPGMA) and band tolerance 1.00% 
2.3.6 Multi-locus sequence typing  
Multi-locus sequence typing (MLST) was performed to define the PFGE clusters and 
identify the E. coli sequence type and clonal complexes. For MLST, 14 isolates were selected 
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from clusters forming units defined by PFGE and 10 isolates which did not form any clusters. 
Isolates were characterized by MLST using previously published scheme including seven 
housekeeping genes: adk, fumC, gyr, icd, mdh, purA, recA (Wirth et al., 2006). With the 
exception of recA the amplification and sequencing were carried out using the primers listed in 
E. coli MLST website (http://mlst.warwick.ac.uk/mlst/dbs/Ecoli/documents/primersColi_html) 
(Table 2.2) (Wirth et al., 2006). For recA new primers were designed in-house and the reaction 
conditions were optimized. Allelic profiles and sequence types were determined via the online 
MLST database (http://mlst.warwick.ac.uk/mlst/dbs/Ecoli).  
2.3.7 Data analysis 
Data obtained from the tests were organized using Microsoft excel and analyzed 
descriptively. 
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Table 2.2: PCR primers used to amplify seven housekeeping genes of E. coli 
Primer 
Name 
Sequence Reference 
adk 
5’ -ATTCTGCTTGGCGCTCCGGG- 3’ 
(Wirth et al., 2006) 
5’ -CCGTCAACTTTCGCGTATTT- 3’ 
fumC 
5’ -GTACGCAGCGAAAAAGATTC  3’ 
(Wirth et al., 2006) 
5’ -TCACAGGTCGCCAGCGCTTC- 3’ 
gyrB 
5’ -TCGGCGACACGGATGACGGC- 3’ 
(Wirth et al., 2006) 
5’ -ATCAGGCCTTCACGCGCATC- 3’ 
icd 
5’ -ATGGAAAGTAAAGTAGTTGTTCCGGCACA- 3’ 
(Wirth et al., 2006) 
5’ -GGACGCAGCAGGATCTGTT- 3’ 
mdh 
5’ -ATGAAAGTCGCAGTCCTCGGCGCTGCTGGCGG- 3’ 
(Wirth et al., 2006) 
5’ -TTAACGAACTCCTGCCCCAGAGCGATATCTTTCTT- 3’ 
purA 
5’ -CGCGCTGATGAAAGAGATGA- 3’ 
(Wirth et al., 2006) 
5’ -CATACGGTAAGCCACGCAGA- 3’ 
recA 
5’ -GTGCGTTTATCGATGCTGAA- 3’ 
This study 
5’ -TCTTTTACGCCCAGGTCAAC- 3’ 
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2.4 Results 
2.4.1 PCR and DNA sequencing 
Of the 99 3GC resistant isolates, 65 were originally cultivated using CHROMagar ESBL 
while 34 were grown on MacConkey agar. Of the 205 flocks sampled, broad-spectrum β-
lactamase producing E. coli were isolated from 56 including 25 producing ESBLs, 30 producing 
AmpC type enzymes and 1 where both types were identified (Table 2.3). Phylogenetic analysis 
of CTX-M sequences revealed that predominant ESBL was CTX-M-1 in 54 isolates and the 
remaining 1 was closely related CTX-M group-1 genes (Table 2.4). CMY-2 was the only AmpC 
type enzyme identified (n=39). Four isolates contained both CTX-M-1 and CMY-2 genes. The 
majority of ESBL producers were detected from isolates grown on CHROMagar ESBL while the 
majority of AmpC producing isolates were recovered from MacConkey agar. 
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Table 2.3: Number of flocks positive for ESBL and AmpC β-lactamase producing E. coli 
 
AmpC Positive Flocks 
Total 
(+) (-) 
ESBL 
Positive 
Flocks 
(+) 1 25 26 (12.7%) 
(-) 30 149 179 (87.3%) 
 
Total 31 (15.1%) 174 (84.9%) 205 
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Table 2.4: Frequency of β-lactamases genes in chickens from small flocks (<300 birds/year) 
 
Ф Two isolates from same sample were positive for ESBL and AmpC differently, so we 
included both two isolates in our study, ╫ Isolates from one sample out of 34 were not positive 
for either ESBL or AmpC. 
  
Samples 
isolated 
from 
No. of 
Samples 
resistant to 
3GC 
No. of samples positive for β-lactamases resistance genes 
CTXM type ESBL CMY Type AmpC 
Both ESBL and 
AmpC 
CHROMagar 
ESBL 
65 Ф 
CTXM -1 (52; 80.0%) 
CTXM-1 like (1; 1.5%) 
CMY- 2 (8; 12.3%) 
CTXM-1 and CMY-
2 (4; 6.2%) 
MacConckey 34 ╫ CTXM -1 (2; 5.9%) CMY- 2 (31; 91.1%) - 
Total 99 55 (55.6%) 39 (39.4%) 4 (4%) 
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2.4.2 Class I integrons 
All 99 3GC resistant isolates were screened for class I integrons and amplicons were 
sequenced revealing 22 isolates possessing 1kb fragments. The aadA1 encoding the protein 
streptomycin 3''-adenylyltransferase which confers resistance to streptomycin and spectomycin 
was identified. Of the integron positive isolates, 11 also carried the CTX-M-1 gene and 11 
isolates possessed CMY-2. 
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2.4.3 Pulsed-field gel electrophoresis  
Of the 261 isolates characterized by PFGE, 226 yielded analyzable banding patterns 
including 80 of 99 β-lactamase producing isolates and 146 out of 162 non-resistant isolates. 
When the banding patterns from all 226 isolates were analyzed together, it was clear that the 
population structure was heterogeneous. A total of 9 clusters (groups of at least 3 isolates with 
≥85% banding similarity), none of which contained more than 6 isolates were identified (Figure 
2.1). A total of 23 β-lactamase producers were found within 7 clusters; only 3 of these clusters 
contained isolates from multiple flocks. Isolates with and without β-lactamase were found 
together in 1 cluster. One cluster comprised of five isolates harboring both class I integrons and 
the CTX-M-1 ESBL. 
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Figure 2.1: Relatedness of isolates as determined by PFGE. Only the cluster forming isolates (32 
out of 226) are represented in this dendrogram. Cluster number is indicated by the violet 
coloured number. Restriction banding patterns (DNA fingerprints) are displayed in the middle. 
The presence of broad spectrum β-lactamases are indicated for each isolate by the ESBL and 
AmpC columns. Cluster analysis was done using GelCompare II, similarities were determined 
using the Dice co-efficient with unweighted pair group method using arithmetic averages 
(UPGMA) and band tolerance 1.00%. 
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2.4.4 MLST 
To characterize the PFGE clusters, 24 isolates were selected. Of them 14 isolates from 9 
clusters defined by PFGE and 10 non-clustering isolates were included. A sequence type was not 
assigned for one isolate, where purA amplicons yielded poor quality sequence. Novel allelic 
combinations and therefore new sequence types were identified in 6 isolates (Table 2.5). MLST 
revealed that all isolates clustering together by PFGE were the same sequence type except for 
cluster number 3 which were closely related two locus variants. There were no predominant STs 
particularly associated with CTX-M-1 productions in Canadian small chickens. Non-clustering 
isolates all had unique sequence types. Four different clonal complexes were identified, while 
ST10 clonal complex was observed in both cluster and non-cluster forming isolates. 
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Table 2.5: Distribution of E. coli sequence types in chickens from small scale farms 
Cluster 
Number 
Sample 
ID 
adk-fumC-gyr-icd-mdh-
purA-recA 
Sequence 
Type 
Clonal complex β-lactamase gene 
1 EC-008 6-31-5-28-1-1-2 ST57  ST350 complex CTX-M-1 
1 EC-087 6-31-5-28-1-1-2 ST57  ST350 complex CTX-M-1 
2 EC-033 6-4-4-16-24-8-14 ST58 ST155 complex CTX-M-1 & CMY-2 
3 EC-001 87-7-231-140-1-187-14 *ST2792 -2 
 
CTX-M-1 
3 EC-024 87-53-231-140-1-187-2 ST2792 
 
CTX-M-1 
4 EC-050 6-11-4-8-8-8-6 ST3270 
 
CTX-M-1 
5 EC-093 6-4-159-44-112-1-17 ST1011 
 
ND 
5 EC-097 6-4-159-44-112-1-17 ST1011 
 
ND 
6 EC-064 6-95-4-18-11-7-14 ST1304 
 
CTX-M-1 
7 EC-080 6-65-344-1-11-13-6 ST3580 
 
CTX-M-1 
8 EC-003 6-4-14-16-24-8-14 ST155 ST155 complex CTX-M-1 
8 EC-180 6-4-14-16-24-8-14 ST155 ST155 complex ND 
9 EC-020 6-11-4-8-8-8-2 ST48 ST10 complex CTX-M-1 
9 EC-108 6-11-4-8-8-8-2 ST48 ST10 complex CTX-M-1 
NC EC-038 6-11-4-8-8-N-2 *ST48 - 1  CTX-M-1 
NC EC-055 6-65-32-26-9-8-2 ST297 
 
CTX-M-1 
NC EC-068 6-31-5-28-1-1-2 ST57  ST350 complex CTX-M-1 
NC EC-107 6-4-15-1-22-1-7 *ST5617 -1 
 
CMY-2 
NC EC-120 10-53-4-8-12-8-2 *ST746 -1 
 
CMY-2 
NC EC-165 6-4-5-26-20-8-14 ST40 ST40 Complex ND 
NC EC-192 6-11-4-8-8-8-2 ST48 ST10 Complex ND 
NC EC-199 111-7-4-8-12-8-2 *ST813 -1 
 
ND 
NC EC-203 6-11-15-1-22-8-7 *ST366 -1 
 
ND 
NC EC-209 10-4-4-8-8-8-2 ST178 ST10 Complex ND 
 
NC = Non-cluster, ND = Not detected; N = poor quality sequence which was not assigned an 
allelic number; *indicates a novel allelic combination, the most similar sequence type and the 
number of loci differing between them are indicated.  
 56 
 
2.5 Discussion 
In Canada, chicken originating from small-scale farms which pass through provincial 
regulated abattoirs are not included in the current national antimicrobial surveillance program 
(Government of Canada, 2015a). Moreover, there were no available data for antimicrobial 
resistance for these backyard chickens. To address this gap, we conducted this study to identify 
broad-spectrum β-lactamase producing E. coli from this understudied bird population. 
We found that among E. coli resistant to 3GC isolated from chickens raised in small flocks 
in southern Ontario, ESBL producing E. coli were isolated from 12.7% flocks tested. In contrast, 
researchers in India were able to detect ESBL producing isolates from 29.4% of commercial 
flocks but failed to identify any ESBLs among birds raised in E. coli from birds raised in free-
range (Samanta et al., 2015). Low levels of resistance were previously reported in backyard 
poultry comparing with intensively farmed poultry in Australia (Obeng et al., 2012). Both these 
studies reported very limited or occasional use of β-lactam drugs in those backyard chicken 
population which has been previously reported to be associated with the presence of resistance to 
these drugs (Agersø et al., 2012; Cohen Stuart et al., 2012; Lowrance et al., 2007; Obeng et al., 
2012; Samanta et al., 2015). In Canada, β-lactam drugs including aminopenicillins, ceftiofur has 
been reported as commonly used drugs to treat E. coli infection in chickens (Agunos et al., 
2012). This might be one of the reasons for the seemingly high frequency of ESBL producing E. 
coli in Canadian backyard chickens. However, there is no data available for antimicrobial use in 
chickens coming from small-scale farms to support this hypothesis. 
ESBLs producing E. coli were observed in higher percentage from the isolates came 
through CHROMagar ESBL (selective media), while AmpC producers were more common in 
isolates grown on MacConkey agar. As CHROMagar ESBL particularly designed to screen 
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ESBLs by inhibiting the growth of AmpC producers (CHROMagar, 2012), finding lower number 
of AmpC producers on CHROMagar ESBL was therefore an expected outcome. Previous studies 
focusing on ESBL and AmpC producers, found that ESBL producing isolates were more 
common than AmpC producers in broiler flocks (Reich et al., 2013). 
CTX-M-1 and CMY-2 were reported as the most frequently detected genes in 3GC 
resistant E. coli strains from chickens raised in small-scale flocks. Our findings are consistent 
with those of a French study where CTX-M and CMY-2 were the predominant broad-spectrum 
β-lactamases in 3GC resistant E. coli in poultry (Baron et al., 2014). Other studies in Europe 
reported a high frequency of CTX-M-1 among E. coli from chickens (Belmar Campos et al., 
2014; Girlich et al., 2007; Randall et al., 2011). Though CTX-M-1 has been frequently 
encountered in animals globally, however, few studies found this gene to a lesser extent from 
human E. coli isolates (Belmar Campos et al., 2014; Blanc et al., 2014; Madec et al., 2015; 
Valentin et al., 2014). CTX-M-15 has been reported to be the most commonly encountered 
human ESBL type around the world (Belmar Campos et al., 2014; Geser et al., 2012b; Reuland 
et al., 2013). In Canada, CTX-M-15 was also identified as the most common ESBL among 
human clinical isolates (Peirano et al., 2010; Zhanel et al., 2010), while our study identified a 
different predominant gene in E. coli from poultry. As humans come into close contact with 
backyard chickens, there is a risk of zoonotic transmission of pathogenic bacteria or other 
organisms harboring mobile resistance genes (Pohjola et al., 2016). However, as we found that 
the predominant ESBLs identified from these birds are different from those most commonly 
encountered in people, this risk may be lower than previously assumed. 
To better understand the relatedness of the resistant isolates in our current study, PFGE 
was performed and 226/261 isolates yielded analyzable banding patterns. Failure to in obtaining 
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analyzable data is consistent with previous studies which found that some strains are non-
typeable by PFGE (Bens et al., 2006; CDC, 2016b). Heterogenous fingerprint patterns were 
found for resistant and susceptible isolates, while few isolates were found to be closely related 
which were together defined as cluster. Of the 9 isolate clusters, 4 contained isolates from the 
same flock, while 5 contained isolates from multiple flocks. Close contact between birds within a 
flocks perhaps explains these findings. The presence of the same β-lactamase gene was identified 
in unrelated isolates, suggesting that the dissemination of this resistance in E. coli colonizing 
chickens was associated with the spread of plasmids rather than particular E. coli clones. These 
findings were consistent with previous studies which found that dissemination of CTX-M genes 
were associated with horizontal transfer of plasmids rather than clonal spread (Girlich et al., 
2007; Liebana et al., 2006), which strengthen our current statement regarding spread of CTX-M 
type ESBL via horizontal gene transfer in Canadian chicken isolates. 
MLST revealed that the majority of the isolates which clustered together by PFGE were 
the same sequence types. Our current findings are in consistence with other studies where they 
found ST10, ST57, ST58, ST155 as predominant STs from chicken E. coli isolates associated 
with ESBL production (Ben Sallem et al., 2014; Overdevest et al., 2011). Four different clonal 
complexes, ST155, ST10, ST350 and ST40 were identified while ST10 clonal complex was 
observed both in cluster forming and non-cluster forming units. Other studies in Canada reported 
ST10 clonal complexes from human clinical infections as well as chicken and franklin gulls 
(Bergeron et al., 2012; Bonnedahl et al., 2015). However, ST131 which is a frequently reported 
E. coli from community onset UTIs globally including Canada, and is often associated with 
CTX-M-15 production (Graham et al., 2016; Peirano et al., 2010; Pitout, 2012a). Interestingly, 
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none of our isolates were identified as ST131 which do not support our hypothesis of findings 
human resistant pandemic clones in Canadian chicken. 
The risk to Canadian public health associated with this resistance infection coming from 
poultry has not yet been adequately investigated. Our study identified CTX-M-1 as predominant 
ESBL type in Chicken which is different than human population. Fingerprinting results showed 
isolates in this current study were heterogeneous. Overall our findings suggest that isolates from 
small flocks pose relatively a low public health risk, although further studies are required to 
determine any link on ESBL producing E. coli from Canadian human and chicken population. 
The dissemination of a single ESBL (CTXM-1) in chickens from different small-scale flocks 
could be due to horizontal transmission of resistant genes between birds possibly occurring at the 
hatchery level. The current study also suggests the importance of using selective media in AMR 
studies to identify an important type of resistance gene such as CTX-M-1 while these genes 
might be undetected if using only non-selective media such as MacConkey.  
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2.6 Transition Statement 
In Canada, the Canadian Integrated Program for Antimicrobial Resistance Surveillance 
(CIPARS) monitors the antimicrobial susceptibility of E. coli from commercial broiler chickens 
slaughtered at federally inspected abattoirs. However, CIPARS does not routinely include any 
description of resistance mechanisms on these isolates which is very important in order to deeper 
understanding of the epidemiology of antimicrobial resistance. Additionally, CIPARS does not 
use any selective media to screen the β-lactamases producing isolates which may lead to an 
underestimation of the prevalence of these enzymes. In our first study, selective media was used 
to identify 3rd generation cephalosporin resistant isolates from small-scale flocks which were 
then screened for β-lactamase genes by PCR. This study on small scales chicken flocks 
highlighted a potential gap in identifying β-lactamase producing E. coli from chickens raised in 
large commercial flocks. In the next chapter, we determined broad-spectrum β-lactamase 
producing genes from large commercial chickens using selective media to address these gaps. 
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3.1 Abstract 
Broad spectrum β-lactamase producing E. coli are emerging in humans and food producing 
animals throughout the world. The objective of this study was to identify ESBL and AmpC 
producing E. coli from commercial broiler chickens raised in Ontario, Canada and to compare 
the use of selective media with the standard CIPARS protocol. Ceacal contents from birds 
passing through federally inspected abattoirs collected in 2013 and 2014 by CIPARS were 
included. These archived ceacal samples were sent to the University of Saskatchewan to 
selectively culture E. coli resistant to the 3GC and identify the broad-spectrum β-lactamases in 
these isolates. A total of 134 isolates were grown on media selective for ESBL producing 
organisms were recovered from 52 of 463 samples (11.4%). Antimicrobial MICs were 
determined for all isolates using the Sensititre® system. A high frequency of resistance towards 
β-lactam drugs; ampicillin (100%), ceftriaxone (92.5%) and ceftiofur (91.7%) was identified. 
Multidrug resistance (resistant to ≥ 3 classes) was observed in 94.8% of isolates. ESBL 
producing isolates were recovered from 35/463 (7.6%) of samples while 12/463 samples were 
positive for AmpC. All ESBL genes detected were identified as CTX-M-1 while 61.3% of 
AmpC genes were CMY-2. In conclusion, our study suggests that using selective media is 
helpful for identifying CTX-M-1 mediated 3GC resistance, which might not be detected using 
non-selective media.  
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3.2 Introduction 
Antimicrobial resistance is an emerging problem throughout the world including Canada. 
In addition to the prospect of untreatable infections, antimicrobial resistance results in higher 
healthcare costs due to longer hospital stays, the requirement for additional diagnostics and more 
expensive drugs (WHO, 2016). β-lactam group drugs are commonly used to treat E. coli 
infection in both humans and animals (Briñas et al., 2002). However, the emergence of extended-
spectrum β-lactamase (ESBL) producing E. coli is a concern in both human and veterinary 
medicine as it confers resistance to most of the β-lactam drugs including 3rd and 4th generation 
cephalosporin (Blaak et al., 2015). AmpC type β-lactamases are also problematic conferring 
resistance to many of the same drugs (Rawat and Nair, 2010).  
TEM (except TEM 1, 2 and 13), SHV (except SHV 1) and CTX-M are common examples 
of ESBLs, the CTXM type enzymes have been dominant worldwide since the early 2000’s 
(Rubin and Pitout, 2014). CMY, FOX, ACT, MOX, ACC, DHA are examples of AmpC type β-
lactamase (Rubin and Pitout, 2014). In poultry and other animals CTX-M-1 was reported as most 
encountered ESBL type in E. coli in Europe (Blaak et al., 2014; Dierikx et al., 2013; Overdevest 
et al., 2011; Randall et al., 2017). In contrast, the majority of human isolates have been found 
carry CTX-M-15 (Valentin et al., 2014). CTX-M-15 has also been identified in the USA and 
Canada as most prevalent resistant gene in humans and associated with the pandemic E. coli 
sequence type 131 (ST131) (Denisuik et al., 2013; Overdevest et al., 2011). Among AmpC type 
β-lactamase in E. coli from hospitalized Canadian patients, CMY-2 was the prevalent variant 
(Denisuik et al., 2013). Another study from Norway found CMY-2 producing extended-spectrum 
cephalosporin-resistant E. coli from retail chicken which were closely related with human 
clinical isolates carrying the same gene suggesting that transmission between poultry and 
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humans is occurring (Berg et al., 2017). Similarly, ESBL producing E. coli from Dutch retail 
chicken meat were found to be indistinguishable to human clinical isolates (Overdevest et al., 
2011). These findings suggest food producing animals particularly chicken meat might be a 
source of resistance genes for humans.  
The Canadian chicken industry is growing and contributes $6.8 billion to Canada’s Gross 
Domestic Product (GDP) (Chicken Farmers of Canada, 2016b). In Canada, per capital 
consumption of chicken meat is 31.86 kilos while beef and pork consumptions are 24.40 and 
22.63 kilos respectively (Government of Canada, 2016b). Chicken is an increasingly large 
portion of the diet and is therefore particularly important as a source of resistance in Canada. 
Ontario is the largest chicken producer in Canada with 1,155 chicken farmers and 42 processors, 
contributing $2.2 billion to Canada’s GDP annually (Chicken Farmers of Canada, 2016b). 
Antimicrobial resistance surveillance in E. coli and other food borne bacteria is important 
for tracking the emergence of resistance and assessing the impact of resistance control strategies 
(Government of Canada, 2015b). The Canadian Integrated Program for Antimicrobial 
Surveillance (CIPARS) is the national resistance surveillance program which monitors 
antimicrobial use and resistance in enteric bacteria from food animals on farm and at slaughter, 
retail meat and human clinical isolates at federal level. Two types of slaughter facilities (federal 
and provincial) exist in Canada (Government of Canada, 2015b). More than 90% food producing 
animals in Canada are processed in these federally inspected abattoirs which included in 
CIPARS sampling (Government of Canada, 2015a).  
CIPARS only uses non-selective media to screen resistant isolates and molecular 
characterization of resistant isolates is also a limitation of their program. We conducted this 
study to determine whether the inclusion of selective media will improve our ability to detect E. 
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coli producing broad-spectrum β-lactamases from large commercial chickens which pass through 
federally inspected abattoirs. 
 
3.3 Materials and Methods 
3.3.1 Study design  
This is a retrospective comparison where samples were re-analyzed using a different 
methodological strategy to compare approaches. Further, this study was performed to determine 
if different genes are responsible for 3GC resistance among E. coli isolated from commercial 
broiler chickens. Archived cecal samples collected by CIPARS from chickens in Ontario in 2013 
and 2014 were included. Broad spectrum β-lactam resistant E. coli were isolated and identified 
using selective culture media. Antimicrobial MICs were determined by broth microdilution. 
Isolated were screened for β-lactamase genes by PCR and DNA sequencing.  
3.3.2 Sample collection and processing by CIPARS 
Chicken caecal contents included in this study were collected by CIPARS from federally 
inspected abattoirs in Ontario in 2013 and 2014. In brief, caecal content from chickens were 
collected to reduce the chances of cross contamination and to better reflect antimicrobial 
resistance in bacteria that originated on the farm (Government of Canada, 2015a). Samples were 
streaked out onto MacConkey agar and E. coli positive isolates were identified. Antimicrobial 
MICs were determined using broth microdilution. Following routine processing, CIPARS froze 
back cecal contents for future studies (Government of Canada, 2015a). 
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3.3.3 Culture and isolation of E. coli using selective and non-selective media 
Frozen caecal samples were shipped from CIPARS on dry ice to the University of 
Saskatchewan. On arrival, samples were streaked on MacConkey agar plate to ensure that viable 
E. coli were present. After incubation at 37°C for overnight, isolates from pink colonies were 
identified and biochemically tested using the citrate, urease and indole tests. Any isolates with 
citrate negative, urease negative, and indole positive were identified as E. coli confirming the 
integrity of the sample.  
All samples were also streaked out onto CHROMagar ESBL, a selective media to detect 
ESBL producing E. coli. Dark pink colonies were considered to be suspected ESBL producers, 
up to 3 colonies were picked and sub-cultured onto 5% sheep agar plates. Colonies from each 
blood agar plates were then identified biochemically and E. coli was stored for further analysis.  
3.3.4 Antibiotic Susceptibility Testing 
Antimicrobial susceptibility testing was performed by broth microdilution using the 
Sensititre system (Trek Diagnostics, Cleveland, OH). The NARMS plate (CMV2AGNF format) 
which includes 15 drugs representing 7 classes was used in this study according to the 
manufacturer’s instructions (Table 3.1). In brief, isolates were sub-cultured on blood agar plate 
and incubated overnight at 37°C. 3-4 colonies were then suspended in 5ml demineralized water 
to a density of 0.5 McFarland to prepare the inoculum. 30 µl of bacterial suspension was added 
to 11ml cation-adjusted Muller Hinton broth (Trek Diagnostics, OH, USA). 50 µl of inoculum 
was dispensed into the 96 well CMV2AGNF plate using the Sensititre auto-inoculator. Plates 
were sealed with adhesive film and incubated at 35°C for 18-22 hours. Antimicrobial MICs were 
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interpreted (classified as susceptible or resistant) according to CLSI guidelines (Table 3.1). For 
quality control, S. aureus ATCC 29213 and E. coli ATCC 25422 were used.  
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Table 3.1: List of drugs with resistance breakpoints used in antibiotic susceptibility testing 
panel  
Drug Class Drug Tested Range Breakpoint 
β-lactams 
 
Cefoxitin 0.5 - 32 ≥32 
Ceftriaxone 0.25 - 64 ≥4 
Amoxicillin-Clavulanic 
acid 
1/0.5 - 32/16 ≥32/16 
Ceftiofur 0.12 - 8 ≥8 
Ampicillin 1 - 32 ≥32 
Phenicol Chloramphenicol 2 - 32 ≥32 
Tetracyclines  Tetracycline 4 - 32 ≥16 
Sulfonamides 
 
Sulfisoxazole 16 - 256 ≥512 
Sulfisoxazole-
Trimethorprim 
0.12/2.38 - 4/76 ≥4 
Quinolones 
 
Ciprofloxacin 0.015 - 4 ≥4 
Nalidixic Acid 0.5 - 32 ≥32 
Macrolides Azithromycin 0.12 - 16 ≥32 
Aminoglycosides 
 
Gentamicin 0.25 - 16 ≥16 
Kanamycin 8 - 64 ≥64 
Streptomycin 32 - 64 ≥64 
 
  
 69 
 
3.3.5 Bacterial DNA extraction and polymerase chain reaction of targeted gene sequences 
Crude DNA extracts (boil preps) of cultures were made in sterile distilled water. In brief, 
bacteria were sub-cultured on blood agar plate overnight at 37°C. In a sterile 1.5ml micro-
centrifuge tube, 200uL of ultrapure water was added and several isolated colonies were 
suspended in it. Tubes were then vortexed and boiled in a heat block for 10 minutes. After 
boiling, tubes were cooled at room temperature for 2 minutes, and centrifuged for 1 minute at 
13000rpm. The supernatant was then transferred to a sterile 1.5 ml micro-centrifuge tube and 
stored at -20°C until used. 
Previously published primers of CTXM-U, CTXMG-1 and CMY-2 gene were used to 
detect ESBL and AmpC genes (Table 3.2). PCR reactions were carried out in 25µL volumes 
including 24µL of mastermix and 1μL of boil prep DNA template was added. In each set of 
reactions, positive and negative controls were included. Thermycycler conditions were as 
follows: initial denaturation at 94°C for 6 mins followed by 35 cycles of denaturation at 94°C for 
1 min, annealing at 61°C (CTX-M-U, CTX-M-G1)/68°C (CMY-2) for 1 min, elongation at 72°C 
for 1 min and final extension at 72°C for 10 mins. Amplicons were resolved by electrophoresis 
using 1% agarose gel at 110 volts for 30 minutes. 3μL of DNA gene Ladder was used to the first 
well. Gels were then visualized under UV light using the AlphaImager® HP (Fisher Scientific, 
Toronto, ON). 
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Table 3.2: PCR primers used to detect ESBL and AmpC β-lactamase genes in E. coli 
Primer Name Primer Sequence References 
CTXM-U 
5’ -ATGTGCAGYACCAGTAARGTKATGGC- 3’ 
(Munday et al., 2004) 
5’ -TGGGTRAARTARGTSACCAGAAYCAGCGG- 3’ 
CTXM-G1 
5’ -GTTGTTAATTCGTCTCTTCC- 3’ 
(Pitout et al., 2004) 
5’ -AGTTTCCCCATTCCGTTTC- 3’ 
CMY-2 
5’ -ATGATGAAAAAATCGTTATGCTGC- 3’ (Kruger et al., 2004) 
5’ -GCTTTTCAAGAATGCGCCAGG- 3’ (Hasman et al., 2005) 
 
  
 71 
 
3.3.6 PCR amplicon purification and nucleotide sequencing  
PCR products were purified using EZ-10 Spin Column PCR purification kit (Bio Basic 
Canada Inc., ON, Canada) and DNA was quantified by spectrophotometrically (NanoDrop™ 
1000). Purified DNA with ~1.8 ratio of absorbance at 260 nm and 280 nm and 2.0 - 2.2 of 
260/230 values were considered to have sufficiently high quality for sequencing. DNA with a 
concentration of 10 - 50ng/μL was then sequenced by a commercial lab using the amplification 
primers. DNA sequences were assembled, edited and analyzed using gap4 and Pregap4 
software’s (part of Staden Package). The identity of contigs generated from sequence analysis 
was determined by comparison to a set of reference sequences listed on Lahey database 
(www.lahey.org) using CLC sequence viewer.  
3.3.7 Data analysis 
All the results were recorded in Microsoft Excel, and analyzed descriptively. 
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3.4 Results  
3.4.1 Recovery of E. coli using selective and non-selective media 
Of the 466 samples tested, E. coli was recovered from 463 samples. Lactose fermenting 
colonies from the remaining 3 samples were observed but were biochemically identified as other 
Enterobacteriaceae species. The recovery rate of the samples was 99.4%. Out of 463 samples, 52 
were found positive on CHROMagar ESBL. Up to 3 isolates were isolated from each sample 
positive on CHROMagar, a total of 134 isolates were identified and frozen at -80°C (Table 3.3).  
  
 73 
 
Table 3.3: Number of E. coli isolates in chickens from large-scale flocks using selective 
media (CHROMagar ESBL) 
Total sample number 466 
Samples from which E. coli was recovered 463 
Samples from which E. coli was recovered on CHROMagar ESBL 52 
Number of isolates recovered from CHROMagar ESBL 134* 
 
*Up to 3 isolates were isolated from each CHROMagar positive sample 
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3.4.2 Antibiotic resistant profile of broad-spectrum β-lactamase producing E. coli 
3.4.2.1 MIC distribution based on drug classes  
The antimicrobial minimum inhibitory concentrations of the 134 isolates recovered from 
CHROMagar were determined, and interpreted based on CLSI guidelines. The MIC distributions 
of isolates to drugs categorized by class are presented in Table 3.4. Overall, no pan-susceptible 
isolates were found, 100% of isolates were resistant to ampicillin while ceftriaxone and ceftiofur 
resistance was observed in 92.5% and 91.7% of isolates respectively. The frequency of resistance 
to cefoxitin and amoxicillin-clavulanic acid was similar including 28.4 and 29.1% of isolates 
respectively. Resistance to sulfamethoxazole-trimethoprim was observed in 23.9% of isolates, 
while 94% of isolates were resistant to potentiated sulfisoxazole. Resistance to tetracycline was 
similarly high observed in 92.5% of isolates. Within a sample, the susceptibility of the three 
isolates recovered was generally homogenous. 
 
  
Table 3.4: Minimum inhibitory concentration distribution of Escherichia coli (n=134) from chickens raised in large-scale farms 
Drug Class Name 
0.01
5 
0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 
%R Isolates 
(n=134) 
%R Samples 
(n=52) 
β-lactam 
Cefoxitin        4 51 34 7 38    38 (28.4) 16 (30.8) 
Ceftriaxone      2 3 5  1 12 34 77   124 (92.5) 48 (92.3) 
Amox Clav         6 77 12 39    39 (29.1) 16 (17.4) 
Ceftiofur       1 7 3 123      123 (91.7) 48 (92.3) 
Ampicillin            134    134 (100) 52 (100) 
Sulfonamides 
Sulfisoxazole           8    126 126 (94.0) 49 (94.2) 
SXT    52 46 4   32       32 (23.9) 13 (25.0) 
Quinolones 
Ciprofloxacin 114 17       3       3 (2.2) 1 (1.9) 
Nalidixic Acid       7 91 32 1  3    3 (2.2) 1 (1.9) 
Aminoglycosides 
Gentamycin     3 47 31 5 1 1 46     46 (34.3) 19 (36.5) 
Kanamycin          107 17 2 8   10 (7.5) 5 (9.6) 
Streptomycin            86 48   48 (35.8) 24 (46.2) 
Tetracyclines Tetracycline         10  1 123    124 (92.5) 49 (94.2) 
Phenicol Chloramphenicol        1 19 93 6 15    15 (11.2) 6 (11.5) 
 
Antimicrobial concentrations for each drug tested are indicated by cells falling between shaded boxes. The red boxes indicate concentrations 
corresponding to resistance. The number of isolates inhibited at each concentration is noted in each cell. %R Isolates indicates the number of 
resistant isolates while %R Samples indicates the number of animals from which an isolate resistant to each drug was isolated.
7
5
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3.4.2.2 MIC distribution based on importance of drugs to human health 
Drugs were also categorized by PHAC based on their importance to human health and the 
MIC distribution was observed based on this in Table 3.5. Resistance to a number of drugs 
classified as “category I - very high importance to human health” was found. Ceftiofur and 
ceftriaxone resistance was identified among 91.7 and 92.5% of isolates respectively. Further, 
isolates were susceptible to drugs listed on “category II - high importance to human health” 
except ampicillin. 
 
  
Table 3.5: Minimum inhibitory concentration distribution of Escherichia coli (n=134) based on PHAC Drug Category 
Importance to 
Human Health* 
Name 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 
%R Isolates 
(n=134) 
%R Samples 
(n=52) 
I – Very high 
importance 
Ceftiofur 
      
1 7 3 123 
     
123 (91.7) 48 (92.3) 
Ceftriaxone 
     
2 3 5 
 
1 12 34 77 
  
124 (92.5) 48 (92.3) 
Amox Clav 
        
6 77 12 39 
   
39 (29.1) 16 (17.4) 
Ciprofloxacin 114 17 
      
3 
      
3 (2.2) 1 (1.9) 
II – High 
importance 
Ampicillin 
           
134 
   
134 (100) 52 (100) 
Cefoxitin 
       
4 51 34 7 38 
   
38 (28.4) 16 (30.8) 
Naladixic Acid 
      
7 91 32 1 
 
3 
   
3 (2.2) 1 (1.9) 
Gentamicin 
    
3 47 31 5 1 1 46 
    
46 (34.3) 19 (36.5) 
Kanamycin 
         
107 17 2 8 
  
10 (7.5) 5 (9.6) 
Streptomycin 
           
86 48 
  
48 (35.8) 24 (4.6) 
SXT 
   
52 46 4 
  
32 
      
32 (23.9) 13 (25.0) 
III – Medium 
importance 
Chloramphenicol 
       
1 19 93 6 15 
   
124 (92.5) 49 (9.4) 
Tetracycline 
        
10 
 
1 123 
   
15 (11.2) 6 (11.5) 
Sulfisoxazole 
          
8 
   
126 126 (94.0) 49 (94.2) 
* Health Canada’s Veterinary Drugs Directorate categorized these drugs based on their importance to human health (Government of Canada, 
n.d.). Antimicrobial concentrations for each drug tested are indicated by cells falling between shaded boxes. The red boxes indicate 
concentrations corresponding to resistance. The number of isolates inhibited at each concentration is noted in each cell. %R Isolates indicates 
the number of resistant isolates while %R Samples indicates the number of animals from which an isolate resistant to each drug was isolated.
7
7
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3.4.2.3 Percentage of isolates and samples resistance to different antimicrobial classes 
No isolates were fully susceptible to all drugs were found. Multidrug resistance, defined 
as resistance to three or more drug classes (Tadesse et al., 2012), was observed in 127 (94.8%) of 
isolates from 50 (96.2%) of samples. Resistance to 5 antimicrobial classes was identified in 
14/134 (10.4%) of isolates from 5 (9.6%) of samples (Table 3.6). No pan-resistant isolates were 
identified. 
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Table 3.6: Percentage of isolates and samples resistance to different antimicrobial classes 
Resistance to Antimicrobial Classes* Isolates (n=134) N (%) Samples (n=52) N (%) 
Fully sensitive 0 0 
Resistant to 1 Antimicrobial Class 4 (2.9) 1 (1.9) 
Resistant to 2 Antimicrobial Classes 3 (2.2) 1 (1.9) 
Resistant to 3 Antimicrobial Classes 62 (46.3) 21 (40.4) 
Resistant to 4 Antimicrobial Classes 51 (38.1) 24 (46.2) 
Resistant to 5 Antimicrobial Classes 14 (10.4) 5 (9.6) 
Resistant to 6 Antimicrobial Classes 0 0 
 
* Drug Classes: β-lactam, sulfonamides, quinolones, aminoglycosides, tetracycline, phenicol 
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3.4.3 Broad-spectrum β-lactamase producing genes by PCR and DNA sequencing 
All 134 isolates were screened for ESBL and AmpC β-lactamases, 89 (66.4%) isolates 
from 35 (7.6%) of samples were found to carry ESBL encoding genes while 31 (23.1%) were 
positive for AmpC from 12 (2.7%) samples. DNA sequencing results revealed that all 89 ESBL 
producing isolates possessed CTX-M-1. 31 isolates were found to harbor CMY type enzymes 
which were determined to be CMY-2 (n=20) and CMY-61 (n=12). Co-location of ESBL and 
AmpC β-lactamases was observed in 3 isolates (2.2%) from 2 (0.4%) samples (Table 3.7). 
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Table 3.7: Number of ESBL and AmpC β-lactamase producing E. coli in chickens from 
large commercial broilers farms in Ontario, Canada 
Classes of β-
lactamase 
genes tested 
Number of samples 
positive for β-lactamases 
genes* (n=463) 
Number of isolates 
positive for β-lactamases 
genes (n = 134) 
β-lactamase alleles  
ESBL 35 (7.6%) 89 (66.4%) CTXM -1 (89; 100%) 
AmpC 12 (2.6%) 31 (23.1%) 
CMY-2 (19; 61.3%) 
CMY -61 (12; 38.7%) 
Both ESBL and 
AmpC 
2 (0.4%) 3 (2.2%) 
CTXM - 1 & CMY-61 (2; 66.7%) 
CTXM-1 & CMY-2 (1; 33.3%) 
 
* Unique isolates from two samples (sample ID: FB393 & FB261) were positive for ESBL and 
AmpC individually, those two isolates are therefore represented in both the ESBL and AmpC 
cells of this table.  
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3.5 Discussion 
Samples collected by CIPARS in 2013 and 2014 from chicken abattoirs in Ontario were 
included in this study. Culture on MacConkey agar resulted in a 99.4% recovery rate indicating 
that sample integrity was intact. This E. coli recovery rate was similar to what CIPARS found in 
the year 2013 (99%; 171/172) indicating that sample viability was not affected by long term 
storage. Other studies also found higher E. coli recovery rate from frozen samples (Green et al., 
2007; Lautenbach et al., 2008), which suggests that frozen samples could be used without loss of 
integrity for a longer period of time. 
In our current study, high resistance to ceftiofur and ceftriaxone and low resistance to 
cefoxitin and amoxicillin-clavulanic were found. This was expected as selective media 
(CHROMagar ESBL) was used in this study which can detect ESBL producing E. coli while 
suppressing the growth of AmpC producing E. coli (CHROMagar, 2012). The inhibitory effect 
of CHROMagar ESBL on AmpC type enzymes could result in selecting against isolates resistant 
to cefoxitin and amoxicillin-clavulanic. In their abattoir surveillance in 2013, CIPARS reported 
that 20.7% of isolates were resistant to these drugs (Government of Canada, 2015b). The current 
study suggests that using selective media to identify broad spectrum β-lactamase producing E. 
coli may be beneficial for detecting important resistance determinants not currently captured 
under current CIPARS surveillance activities. In the USA, a trend of increasing MDR in E. coli 
was observed from the 1950s when 7.2% of isolates were MDR to the 2000s when 63.6% of 
isolates were MDR (Tadesse et al., 2012). This is indicating that MDR is emerging among 
poultry isolates. In current study, majority of the isolates (94.8%) grown on CHROMagar ESBL 
showed MDR which suggests that selective media could aid in tracking MDR organisms. Using 
selective media, our study found ESBL producers 7.6% (35/463) of the E. coli positive samples. 
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Our current findings are in contrast with few European studies where a higher prevalence 
(>60%) of ESBL producing Enterobacteriaceae from chicken retail meat were identified (Doi et 
al., 2010; Overdevest et al., 2011). Geographical location, farm density and management 
practices might be the reasons behind lower ESBL resistance in Canada. 
The dominance of CTM-X-1 in our study concurs with other reports where CTX-M-1 was 
found as the most prevalent ESBL type in chicken and other food producing animals (Agersø et 
al., 2012; Belmar Campos et al., 2014; Horton et al., 2011; Kola et al., 2012; Valentin et al., 
2014). Additionally, our findings are in consistent with other studies where they found CMY-2 
producing E. coli as predominant AmpC type in Chicken (Börjesson et al., 2013; Botelho et al., 
2015). The extensive use of broad-spectrum cephalosporins was postulated as a reason for with 
the spread of CTX-M type ESBL (Hsu et al., 2010; Zhanel et al., 2010). A significant 
relationship between use of ceftiofur in chicken and incidence of ceftiofur resistant in humans 
and retail chickens was identified in Quebec indicating the link between drug animals and people 
(Dutil et al., 2010). However, CTX-M-15 E. coli is the most frequently encountered ESBL type 
in people worldwide including Canada (Leistner et al., 2014; Peirano et al., 2012, 2010; Valentin 
et al., 2014; Voets et al., 2012; Zhanel et al., 2010), while this study encountered a different 
ESBL type (CTX-M-1) in E. coli from Canadian large commercial broiler chickens. Different 
ESBL type in Canadian chickens comparing with human AMR data suggests that large 
commercial broiler flocks may not pose a high public health risk. However, more studies are 
required to evaluate the transmissibility of resistant gene baring mobile genetic elements between 
E. coli from commercial broiler chickens in Canada and humans. 
Our study demonstrates that surveillance programs may find it useful to include selective 
media to identify organisms resistant to drug classes of particular interest, including ESBL 
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producing E. coli. One study found using selective media could help to determine ESBL 
producing E. coli (Randall et al., 2017). A variety of chromogenic media including CHROMagar 
ESBL, Brillance ESBL can be used as selective media for the detection of ESBL producing E. 
coli. The inclusion of ceftazidime and cefotaxime can help in detecting CTX-M type ESBLs 
whereas cefpodoxime alone can be used to detect other TEM and SHV type ESBLs (European 
Centre for Disease Prevention and Control, 2014).  
In this study CTX-M-1 was found to be the predominant ESBL type in E. coli from 
chickens raised large flocks in Ontario; consistent with our previous investigation where the 
same gene was identified in isolates from small flocks. Chickens from large and small scales 
flocks are different in terms of bird population, management system, drug use, veterinary care. 
However, finding same resistant determinants suggests that resistant genes encoding on mobile 
genetic elements could be disseminated via horizontal transfer within bird’s population. 
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4 General Discussion and Conclusion 
4.1 General discussion 
Antimicrobial resistance in Gram-negative bacteria is increasing throughout the world 
(Kuenzli, 2016; Laxminarayan et al., 2013; Paterson, 2006). Food producing animals including 
chickens are important zoonotic reservoirs of drug resistance determinants in the community. In 
Canada, the majority of the birds are slaughtered in federally inspected abattoirs while a small 
portion originating from small scale flocks pass through provincially inspected facilities 
(Government of Canada, 2015a). Although birds passing through federal inspected abattoirs are 
routinely included in resistance surveillance programs, no data are available about the 
antimicrobial resistance genes responsible for these phenotypes.  (Government of Canada, 
2015a). Another gap is the failure to include E. coli from chickens reared in small flocks in 
current surveillance programs. Several factors which may be associated with a different level of 
risk of resistance in small flocks include poorer biosecurity, high disease burden and less 
veterinary consultation. Furthermore, the relatively close contact with these chickens may be 
associated with unique risks. Finally, the increasing volume of chicken consumed highlights the 
increasing opportunities for the zoonotic transmission of poultry E. coli (Bergeron et al., 2012). 
In these present investigations, these gaps were addressed by studying E. coli from Ontario 
chickens. 
We performed our first study on characterizing broad spectrum β-lactamase producing E. 
coli isolated from chickens raised in small scale flocks. Our study identified ESBL producing E. 
coli in chickens from 26/209 (12.7%) of small flocks sampled, which was less common 
compared to studies from other parts of the world (Doi et al., 2010; Overdevest et al., 2011). We 
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found that the CTX-M-1 β-lactamase was the predominant ESBL identified in small scale 
chickens in agreement with studies of agricultural animals from other countries (Belmar Campos 
et al., 2014; Girlich et al., 2007; Randall et al., 2011). This is in contrast to what is found in 
people in Canada where CTX-M-15 is most common (Peirano et al., 2010). One study in Canada 
identified a link between ceftiofur use in chicken population and increased resistance to ceftiofur 
in human population (Dutil et al., 2010), which indicates of having a similar resistance pattern in 
Canadian chickens and human isolates. However, our findings suggest that the ESBLs associated 
with chickens raised in small flocks are different than those found in the human population; this 
indicates that the zoonotic transmission of these genes occurs less commonly than would be 
expected based on phenotypic resistance alone. To demonstrate relatedness among isolates and 
find out resistant gene transfer pattern, we performed PFGE on these isolates. DNA 
fingerprinting demonstrated that these isolates were genetically diverse suggesting that resistance 
determinants in Ontario chickens might be transferred horizontally rather clonally, the CTX-M-1 
gene is well recognized to be located on plasmids (Karim et al., 2001). These results were 
consistent with previous studies which found that CTX-M-1 producing E. coli isolates were 
genetically heterogenous (as determined by PFGE) and also concluded that plasmid mediated 
horizontal gene transfer plays an important role in the dissemination of the CTX-M-1 ESBL (de 
Been et al., 2014; Girlich et al., 2007; Liebana et al., 2006). Extra-intestinal pathogenic E. coli  
belonging to sequence type 131 (ST131) are a common cause of human urinary tract infections 
and are associated with CTX-M-15 production (Madigan et al., 2015). This strain has been 
previously from retail chicken meat in USA, Italy suggesting that chicken may be a potential 
reservoir of ST131 in the community, and therefore a zoonotic risk (Ghodousi et al., 2016; 
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Johnson et al., 2017). In the present study, none of the isolates tested by MLST were ST131 
suggesting that this strain is uncommon among chickens from small flocks.  
Our findings from small-scale flocks triggered an investigation to determine which broad-
spectrum β-lactamases are found in E. coli from chickens raised in large commercial flocks. 
Furthermore, as the CIPARS program does not use any selective media, we sought to investigate 
this potential gap in the program’s ability to detect important resistant determinants; selective 
media have previously been shown to be useful in the detection of ESBL producing E. coli in 
surveillance studies (European Centre for Disease Prevention and Control, 2014; Swarna et al., 
2015). In our study, we found that the inclusion of selective media allowed us to detect a 
population of multidrug-resistant organisms which would have otherwise been missed. Despite 
the differences between small and large flocks, CTX-M-1 was also identified as predominant 
ESBL in this investigation. These findings suggest that despite differences between small and 
large-scale chicken flocks in Ontario, there may be a common source of ESBL genes possibly 
including: hatcheries, breeder farms or the environments.  
Links between the use of antibiotics in chickens and the presence of resistant organisms 
have been previously described (Agersø et al., 2012; Cohen Stuart et al., 2012; Lowrance et al., 
2007). Although we do not have sufficient antimicrobial usage data in chickens in Canada, one 
explanation for lower rates of resistance could be a low or decreasing rate of 3rd generation 
cephalosporin use in poultry (Chicken Farmers of Canada, 2017). As ceftiofur use has been 
decreased in Canada, thus it will be interesting to see rates of ceftiofur resistance and the 
prevalence of the ESBLs to demonstrate the link between AMU and AMR. Further, ceftiofur is 
categorized as Category I drug based on importance to human health (Government of Canada, 
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2009), continuous monitoring on antimicrobial resistance on this chicken population is extremely 
important to prevent and control any future outbreak. 
Our studies had few limitations. We tested a selection of isolates by MLST, it might be 
possible that we were fail to detect E. coli ST131 from rest of the isolates where were not 
included. Further, isolates were selectively cultured on CHROMagar ESBL to phenotypically 
detect ESBL producers, thus this study was not able to provide actual AmpC producers rate in 
Canadian chickens. 
4.2 Future directions 
This study provides the first description of the presence of ESBL and AmpC type β-
lactamases in E. coli isolated from chickens in Canada. Performing similar studies in other 
agricultural animals to determine the association of resistance pattern and resistance gene types 
between animal species will help to better understand the epidemiology of antimicrobial 
resistance. Future studies to identify risk factors associated with the dissemination of ESBLs 
would be beneficial to inform evidence-based policy to control the spread of these resistance 
determinants. Furthermore, determining the genetic relatedness of E. coli from small and large-
scale chicken production may help to understand the epidemiology of resistance. Moreover, it 
will also be interesting to compare ESBL producing E. coli isolates from human and chicken 
population to find out any association in terms of resistance. 
4.3 General conclusion 
▪ The use of selective media in AMR studies can help to identify ESBL producing E. coli 
which could be missed. 
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▪ CTX-M-1 and CMY-2 were the mostly encountered ESBL and AmpC types in chickens 
from Canadian small and large-scale flocks. 
▪ Horizontal gene transfer is playing an important role in transferring antimicrobial 
resistance determinants in Canadian chickens. 
▪ Public health risk appears to be lower than previously assumed at least for ESBLs. 
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